- Calcium & bone metabolism
- Effects of Endocrine-Disrupting Chemicals on Bone Health
-
So Young Park, Sung Hye Kong, Kyoung Jin Kim, Seong Hee Ahn, Namki Hong, Jeonghoon Ha, Sihoon Lee, Han Seok Choi, Ki-Hyun Baek, Jung-Eun Kim, Sang Wan Kim, on Behalf of Metabolic Bone Disease Study Group of Korean Endocrine Society
-
Endocrinol Metab. 2024;39(4):539-551. Published online July 17, 2024
-
DOI: https://doi.org/10.3803/EnM.2024.1963
-
-
Abstract
PDFPubReader ePub
- This comprehensive review critically examines the detrimental impacts of endocrine-disrupting chemicals (EDCs) on bone health, with a specific focus on substances such as bisphenol A (BPA), per- and polyfluoroalkyl substances (PFASs), phthalates, and dioxins. These EDCs, by interfering with the endocrine system’s normal functioning, pose a significant risk to bone metabolism, potentially leading to a heightened susceptibility to bone-related disorders and diseases. Notably, BPA has been shown to inhibit the differentiation of osteoblasts and promote the apoptosis of osteoblasts, which results in altered bone turnover status. PFASs, known for their environmental persistence and ability to bioaccumulate in the human body, have been linked to an increased osteoporosis risk. Similarly, phthalates, which are widely used in the production of plastics, have been associated with adverse bone health outcomes, showing an inverse relationship between phthalate exposure and bone mineral density. Dioxins present a more complex picture, with research findings suggesting both potential benefits and adverse effects on bone structure and density, depending on factors such as the timing and level of exposure. This review underscores the urgent need for further research to better understand the specific pathways through which EDCs affect bone health and to develop targeted strategies for mitigating their potentially harmful impacts.
- Diabetes, obesity and metabolism
- Reference Standards for C-Peptide in Korean Population: A Korean Endocrine Hormone Reference Standard Data Center Study
-
Jooyoung Cho, Ho-Chan Cho, Ohk-Hyun Ryu, Hyo-Jeong Kim, Chang Geun Kim, Young Ran Yun, Choon Hee Chung, on Behalf of the Task Force Team for Korean Hormone Reference Standards
-
Endocrinol Metab. 2024;39(3):489-499. Published online May 9, 2024
-
DOI: https://doi.org/10.3803/EnM.2023.1888
-
-
Abstract
PDFSupplementary MaterialPubReader ePub
- Background
The Korean Endocrine Hormone Reference Standard Data Center (KEHRS DC) has created reference standards (RSs) for endocrine hormones since 2020. This study is the first of its kind, wherein the KEHRS DC established RSs for serum Cpeptide levels in a healthy Korean population.
Methods Healthy Korean adults were recruited from May 2021 to September 2023. After excluding participants according to our criteria, serum samples were collected; each participant could then choose between fasting glucose only or fasting glucose plus an oral glucose tolerance test (OGTT). If their sample showed high glucose (≥100 mg/dL) or hemoglobin A1c (HbA1c) (≥5.70%), their C-peptide levels were excluded from analyzing the RSs.
Results A total of 1,532 participants were recruited; however, only the data of 1,050 participants were analyzed after excluding those whose samples showed hyperglycemia or high HbA1c. Post-30-minute OGTT data from 342 subjects and post-120-minute OGTT data from 351 subjects were used. The means±2 standard deviations and expanded uncertainties of fasting, post-30-minute and 120-minute OGTT C-peptide levels were 1.26±0.82 and 0.34–3.18, 4.74±3.57 and 1.14–8.33, and 4.85±3.58 and 1.25–8.34 ng/mL, respectively. Serum C-peptide levels correlated with obesity, serum glucose levels, and HbA1c levels.
Conclusion The RSs for serum C-peptide levels established in this study are expected to be useful in both clinical and related fields.
- Calcium & bone metabolism
- Bone Loss after Solid Organ Transplantation: A Review of Organ-Specific Considerations
-
Kyoung Jin Kim, Jeonghoon Ha, Sang Wan Kim, Jung-Eun Kim, Sihoon Lee, Han Seok Choi, Namki Hong, Sung Hye Kong, Seong Hee Ahn, So Young Park, Ki-Hyun Baek, on Behalf of Metabolic Bone Disease Study Group of Korean Endocrine Society
-
Endocrinol Metab. 2024;39(2):267-282. Published online April 25, 2024
-
DOI: https://doi.org/10.3803/EnM.2024.1939
-
-
Abstract
PDFPubReader ePub
- This review article investigates solid organ transplantation-induced osteoporosis, a critical yet often overlooked issue, emphasizing its significance in post-transplant care. The initial sections provide a comprehensive understanding of the prevalence and multifactorial pathogenesis of transplantation osteoporosis, including factors such as deteriorating post-transplantation health, hormonal changes, and the impact of immunosuppressive medications. Furthermore, the review is dedicated to organ-specific considerations in transplantation osteoporosis, with separate analyses for kidney, liver, heart, and lung transplantations. Each section elucidates the unique challenges and management strategies pertinent to transplantation osteoporosis in relation to each organ type, highlighting the necessity of an organ-specific approach to fully understand the diverse manifestations and implications of transplantation osteoporosis. This review underscores the importance of this topic in transplant medicine, aiming to enhance awareness and knowledge among clinicians and researchers. By comprehensively examining transplantation osteoporosis, this study contributes to the development of improved management and care strategies, ultimately leading to improved patient outcomes in this vulnerable group. This detailed review serves as an essential resource for those involved in the complex multidisciplinary care of transplant recipients.
- Adrenal gland
- 2023 Korean Endocrine Society Consensus Guidelines for the Diagnosis and Management of Primary Aldosteronism
-
Jeonghoon Ha, Jung Hwan Park, Kyoung Jin Kim, Jung Hee Kim, Kyong Yeun Jung, Jeongmin Lee, Jong Han Choi, Seung Hun Lee, Namki Hong, Jung Soo Lim, Byung Kwan Park, Jung-Han Kim, Kyeong Cheon Jung, Jooyoung Cho, Mi-kyung Kim, Choon Hee Chung, The Committee of Clinical Practice Guideline of Korean Endocrine Society, The Korean Adrenal Study Group of Korean Endocrine Society
-
Endocrinol Metab. 2023;38(6):597-618. Published online October 13, 2023
-
DOI: https://doi.org/10.3803/EnM.2023.1789
-
-
6,085
View
-
762
Download
-
4
Web of Science
-
5
Crossref
-
Abstract
PDFPubReader ePub
- Primary aldosteronism (PA) is a common, yet underdiagnosed cause of secondary hypertension. It is characterized by an overproduction of aldosterone, leading to hypertension and/or hypokalemia. Despite affecting between 5.9% and 34% of patients with hypertension, PA is frequently missed due to a lack of clinical awareness and systematic screening, which can result in significant cardiovascular complications. To address this, medical societies have developed clinical practice guidelines to improve the management of hypertension and PA. The Korean Endocrine Society, drawing on a wealth of research, has formulated new guidelines for PA. A task force has been established to prepare PA guidelines, which encompass epidemiology, pathophysiology, clinical presentation, diagnosis, treatment, and follow-up care. The Korean clinical guidelines for PA aim to deliver an evidence-based protocol for PA diagnosis, treatment, and patient monitoring. These guidelines are anticipated to ease the burden of this potentially curable condition.
-
Citations
Citations to this article as recorded by
- Correlation of Histopathologic Subtypes of Primary Aldosteronism with Clinical Phenotypes and Postsurgical Outcomes
Chang Ho Ahn, You-Bin Lee, Jae Hyeon Kim, Young Lyun Oh, Jung Hee Kim, Kyeong Cheon Jung The Journal of Clinical Endocrinology & Metabolism.2024; 109(8): e1582. CrossRef - Temporal trends in clinical features of patients with primary aldosteronism over 20 years
Seung Shin Park, Chang Ho Ahn, Sang Wan Kim, Jung-Min Koh, Seung Hun Lee, Jung Hee Kim Hypertension Research.2024; 47(8): 2019. CrossRef - Primary aldosteronism: An underdiagnosed clinical entity
Peeyush Jain, Atul Kaushik, Nilashish Dey, Ashwani Mehta, Shaloo Kapoor, Chhavi Agrawal Journal of Current Cardiology.2024; 2(2): 65. CrossRef - Historical changes in the clinical features of primary aldosteronism
Takamasa Ichijo Hypertension Research.2024;[Epub] CrossRef - Comparing ARR Versus Suppressed PRA as Screening Tests for Primary Aldosteronism
Marco Marcelli, Caixia Bi, John W. Funder, Michael J. McPhaul Hypertension.2024; 81(10): 2072. CrossRef
- Adrenal gland
- 2023 Korean Endocrine Society Consensus Guidelines for the Diagnosis and Management of Primary Aldosteronism
-
Jeonghoon Ha, Jung Hwan Park, Kyoung Jin Kim, Jung Hee Kim, Kyong Yeun Jung, Jeongmin Lee, Jong Han Choi, Seung Hun Lee, Namki Hong, Jung Soo Lim, Byung Kwan Park, Jung-Han Kim, Kyeong Cheon Jung, Jooyoung Cho, Mi-kyung Kim, Choon Hee Chung, The Committee of Clinical Practice Guideline of Korean Endocrine Society, The Korean Adrenal Study Group of Korean Endocrine Society
-
Endocrinol Metab. 2023;38(6):597-618. Published online October 13, 2023
-
DOI: https://doi.org/10.3803/EnM.2023.1789
-
-
6,085
View
-
762
Download
-
4
Web of Science
-
5
Crossref
-
Abstract
PDFPubReader ePub
- Primary aldosteronism (PA) is a common, yet underdiagnosed cause of secondary hypertension. It is characterized by an overproduction of aldosterone, leading to hypertension and/or hypokalemia. Despite affecting between 5.9% and 34% of patients with hypertension, PA is frequently missed due to a lack of clinical awareness and systematic screening, which can result in significant cardiovascular complications. To address this, medical societies have developed clinical practice guidelines to improve the management of hypertension and PA. The Korean Endocrine Society, drawing on a wealth of research, has formulated new guidelines for PA. A task force has been established to prepare PA guidelines, which encompass epidemiology, pathophysiology, clinical presentation, diagnosis, treatment, and follow-up care. The Korean clinical guidelines for PA aim to deliver an evidence-based protocol for PA diagnosis, treatment, and patient monitoring. These guidelines are anticipated to ease the burden of this potentially curable condition.
-
Citations
Citations to this article as recorded by
- Correlation of Histopathologic Subtypes of Primary Aldosteronism with Clinical Phenotypes and Postsurgical Outcomes
Chang Ho Ahn, You-Bin Lee, Jae Hyeon Kim, Young Lyun Oh, Jung Hee Kim, Kyeong Cheon Jung The Journal of Clinical Endocrinology & Metabolism.2024; 109(8): e1582. CrossRef - Temporal trends in clinical features of patients with primary aldosteronism over 20 years
Seung Shin Park, Chang Ho Ahn, Sang Wan Kim, Jung-Min Koh, Seung Hun Lee, Jung Hee Kim Hypertension Research.2024; 47(8): 2019. CrossRef - Primary aldosteronism: An underdiagnosed clinical entity
Peeyush Jain, Atul Kaushik, Nilashish Dey, Ashwani Mehta, Shaloo Kapoor, Chhavi Agrawal Journal of Current Cardiology.2024; 2(2): 65. CrossRef - Historical changes in the clinical features of primary aldosteronism
Takamasa Ichijo Hypertension Research.2024;[Epub] CrossRef - Comparing ARR Versus Suppressed PRA as Screening Tests for Primary Aldosteronism
Marco Marcelli, Caixia Bi, John W. Funder, Michael J. McPhaul Hypertension.2024; 81(10): 2072. CrossRef
- Diabetes, obesity and metabolism
Big Data Articles (National Health Insurance Service Database)
- Risk of Cause-Specific Mortality across Glucose Spectrum in Elderly People: A Nationwide Population-Based Cohort Study
-
Joonyub Lee, Hun-Sung Kim, Kee-Ho Song, Soon Jib Yoo, Kyungdo Han, Seung-Hwan Lee, Committee of Big Data, Korean Endocrine Society
-
Endocrinol Metab. 2023;38(5):525-537. Published online September 7, 2023
-
DOI: https://doi.org/10.3803/EnM.2023.1765
-
-
2,442
View
-
108
Download
-
2
Web of Science
-
4
Crossref
-
Abstract
PDFSupplementary MaterialPubReader ePub
- Background
This study investigated the risk of cause-specific mortality according to glucose tolerance status in elderly South Koreans.
Methods A total of 1,292,264 individuals aged ≥65 years who received health examinations in 2009 were identified from the National Health Information Database. Participants were classified as normal glucose tolerance, impaired fasting glucose, newly-diagnosed diabetes, early diabetes (oral hypoglycemic agents ≤2), or advanced diabetes (oral hypoglycemic agents ≥3 or insulin). The risk of system-specific and disease-specific deaths was estimated using multivariate Cox proportional hazards analysis.
Results During a median follow-up of 8.41 years, 257,356 deaths were recorded. Diabetes was associated with significantly higher risk of all-cause mortality (hazard ratio [HR], 1.58; 95% confidence interval [CI], 1.57 to 1.60); death due to circulatory (HR, 1.49; 95% CI, 1.46 to 1.52), respiratory (HR, 1.51; 95% CI, 1.47 to 1.55), and genitourinary systems (HR, 2.22; 95% CI, 2.10 to 2.35); and neoplasms (HR, 1.30; 95% CI, 1.28 to 1.32). Diabetes was also associated with a significantly higher risk of death due to ischemic heart disease (HR, 1.70; 95% CI, 1.63 to 1.76), cerebrovascular disease (HR, 1.46; 95% CI, 1.41 to 1.50), pneumonia (HR, 1.69; 95% CI, 1.63 to 1.76), and acute or chronic kidney disease (HR, 2.23; 95% CI, 2.09 to 2.38). There was a stepwise increase in the risk of death across the glucose spectrum (P for trend <0.0001). Stroke, heart failure, or chronic kidney disease increased the risk of all-cause mortality at every stage of glucose intolerance.
Conclusion A dose-dependent association between the risk of mortality from various causes and severity of glucose tolerance was noted in the elderly population.
-
Citations
Citations to this article as recorded by
- Effect of glucose variability on the mortality of adults aged 75 years and over during the first year of the COVID-19 pandemic
Miguel A. Salinero-Fort, F. Javier San Andrés-Rebollo, Juan Cárdenas-Valladolid, José Mostaza, Carlos Lahoz, Fernando Rodriguez-Artalejo, Paloma Gómez-Campelo, Pilar Vich-Pérez, Rodrigo Jiménez-García, José M. de-Miguel-Yanes, Javier Maroto-Rodriguez, Bel BMC Geriatrics.2024;[Epub] CrossRef - Islet transplantation in Korea
Joonyub Lee, Kun‐Ho Yoon Journal of Diabetes Investigation.2024; 15(9): 1165. CrossRef - All-cause and cause-specific mortality risks in individuals with diabetes living alone: A large-scale population-based cohort study
Jae-Seung Yun, Kyungdo Han, Bongseong Kim, Seung-Hyun Ko, Hyuk-Sang Kwon, Yu-Bae Ahn, Yong-Moon Mark Park, Seung-Hwan Lee Diabetes Research and Clinical Practice.2024; 217: 111876. CrossRef - The Characteristics and Risk of Mortality in the Elderly Korean Population
Sunghwan Suh Endocrinology and Metabolism.2023; 38(5): 522. CrossRef
- Miscellaneous
- Immune Checkpoint Inhibitors and Endocrine Disorders: A Position Statement from the Korean Endocrine Society
-
Hyemi Kwon, Eun Roh, Chang Ho Ahn, Hee Kyung Kim, Cheol Ryong Ku, Kyong Yeun Jung, Ju Hee Lee, Eun Heui Kim, Sunghwan Suh, Sangmo Hong, Jeonghoon Ha, Jun Sung Moon, Jin Hwa Kim, Mi-kyung Kim, The Committee of Clinical Practice Guideline of the Korean Endocrine Society
-
Endocrinol Metab. 2022;37(6):839-850. Published online December 26, 2022
-
DOI: https://doi.org/10.3803/EnM.2022.1627
-
-
4,571
View
-
340
Download
-
2
Web of Science
-
3
Crossref
-
Abstract
PDFPubReader ePub
- Immune checkpoint inhibitors (ICIs) including an anti-cytotoxic T-lymphocyte-associated antigen 4 inhibitor, anti-programmed cell death protein 1 (PD-1) inhibitors, and anti-PD-ligand 1 inhibitors are representative therapeutics for various malignancies. In oncology, the application of ICIs is currently expanding to a wider range of malignancies due to their remarkable clinical outcomes. ICIs target immune checkpoints which suppress the activity of T-cells that are specific for tumor antigens, thereby allowing tumor cells to escape the immune response. However, immune checkpoints also play a crucial role in preventing autoimmune reactions. Therefore, ICIs targeting immune checkpoints can trigger various immune-related adverse events (irAEs), especially in endocrine organs. Considering the endocrine organs that are frequently involved, irAEs associated endocrinopathies are frequently life-threatening and have unfavorable clinical implications for patients. However, there are very limited data from large clinical trials that would inform the development of clinical guidelines for patients with irAEs associated endocrinopathies. Considering the current clinical situation, in which the scope and scale of the application of ICIs are increasing, position statements from clinical specialists play an essential role in providing the appropriate recommendations based on both medical evidence and clinical experience. As endocrinologists, we would like to present precautions and recommendations for the management of immune-related endocrine disorders, especially those involving the adrenal, thyroid, and pituitary glands caused by ICIs.
-
Citations
Citations to this article as recorded by
- Patterns of hormonal changes in hypophysitis by immune checkpoint inhibitor
Hyunji Sang, Yun Kyung Cho, Sang-hyeok Go, Hwa Jung Kim, Eun Hee Koh The Korean Journal of Internal Medicine.2024; 39(5): 801. CrossRef - Pembrolizumab plus lenvatinib for radically unresectable or metastatic renal cell carcinoma in the Japanese population
Ryo Fujiwara, Takeshi yuasa, kenichi kobayashi, tetsuya yoshida, susumu kageyama Expert Review of Anticancer Therapy.2023; 23(5): 461. CrossRef - Incidence of Endocrine-Related Dysfunction in Patients Treated with New Immune Checkpoint Inhibitors: A Meta-Analysis and Comprehensive Review
Won Sang Yoo, Eu Jeong Ku, Eun Kyung Lee, Hwa Young Ahn Endocrinology and Metabolism.2023; 38(6): 750. CrossRef
- Diabetes, Obesity and Metabolism
Big Data Articles (National Health Insurance Service Database)
- Association of High-Density Lipoprotein Cholesterol Phenotypes with the Risk of Cardiovascular Diseases and Mortality: A Cohort Study in Korea
-
Ga Eun Nam, Youn Huh, Jin-Hyung Jung, Kyungdo Han, Seon Mee Kim, on Behalf of the Taskforce Team of the Obesity Fact Sheet of the Korean Society for the Study of Obesity
-
Endocrinol Metab. 2022;37(2):261-271. Published online April 25, 2022
-
DOI: https://doi.org/10.3803/EnM.2021.1259
-
-
4,214
View
-
153
Download
-
3
Web of Science
-
3
Crossref
-
Abstract
PDFSupplementary MaterialPubReader ePub
- Background
We investigated whether low high-density lipoprotein cholesterol (HDL-C) and isolated and non-isolated low HDL-C levels are associated with the risk of cardiovascular diseases and all-cause mortality among Korean adults.
Methods We included 8,665,841 individuals aged ≥20 years who had undergone a health examination provided by the Korean National Health Insurance Service (NHIS) in 2009 and were followed up until the end of 2018. The hazard ratios (HRs) and 95% confidence intervals (CIs) for study outcomes were calculated using multivariable Cox proportional hazard regression analysis.
Results During the 8.2 years of mean follow-up, myocardial infarction (MI), stroke, and all-cause mortality occurred in 81,431, 110,996, and 244,309 individuals, respectively. After adjusting for confounding variables (model 3), individuals with low HDL-C and lower HDL quartiles were associated with significantly increased risks of all three outcomes, compared to those with normal HDL-C and highest HDL-C quartile (all P<0.001), respectively. HRs for incident MI (1.28; 95% CI, 1.26 to 1.30), stroke (1.13; 95% CI, 1.11 to 1.15), and all-cause mortality (1.07; 95% CI, 1.05 to 1.08) increased in the non-isolated low HDL-C group compared to the normal HDL-C group. Isolated low HDL-C also showed an increase in the HRs of incident stroke (1.06; 95% CI, 1.04 to 1.08) and all-cause mortality (1.30; 95% CI, 1.28 to 1.32).
Conclusion Low HDL-C and non-isolated low HDL-C were associated with increased risk of MI, stroke, and all-cause mortality, and isolated low HDL-C was associated with incident stroke and all-cause mortality risk.
-
Citations
Citations to this article as recorded by
- Association between HDL levels and stroke outcomes in the Arab population
Aizaz Ali, Omar Obaid, Naveed Akhtar, Rahul Rao, Syed Haroon Tora, Ashfaq Shuaib Scientific Reports.2024;[Epub] CrossRef - Association of adiposity and fitness with triglyceride-to-high-density lipoprotein cholesterol ratio in youth
Danladi Ibrahim Musa, Abel Lamina Toriola, Nurudeen O Abubakar, Sunday Omachi, Victor B Olowoleni, Kolade B Ayodele Annals of Pediatric Cardiology.2023; 16(3): 194. CrossRef - Association between cholesterol levels and dementia risk according to the presence of diabetes and statin use: a nationwide cohort study
You-Bin Lee, Min Young Kim, Kyungdo Han, Bongsung Kim, Jiyun Park, Gyuri Kim, Kyu Yeon Hur, Jae Hyeon Kim, Sang-Man Jin Scientific Reports.2022;[Epub] CrossRef
- Miscellaneous
- COVID-19 Vaccination for Endocrine Patients: A Position Statement from the Korean Endocrine Society
-
Cheol Ryong Ku, Kyong Yeun Jung, Chang Ho Ahn, Jun Sung Moon, Ju Hee Lee, Eun Heui Kim, Hyemi Kwon, Hee Kyung Kim, Sunghwan Suh, Sangmo Hong, Jeonghoon Ha, Eun Roh, Jin Hwa Kim, Mi-kyung Kim, the Committee of Clinical Practice Guideline of the Korean Endocrine Society
-
Endocrinol Metab. 2021;36(4):757-765. Published online August 17, 2021
-
DOI: https://doi.org/10.3803/EnM.2021.404
-
-
11,565
View
-
425
Download
-
20
Web of Science
-
21
Crossref
-
Abstract
PDFPubReader ePub
- Since the first outbreak of coronavirus disease 2019 (COVID-19), ongoing efforts have been made to discover an efficacious vaccine against COVID-19 to combat the pandemic. In most countries, both mRNA and DNA vaccines have been administered, and their side effects have also been reported. The clinical course of COVID-19 and the effects of vaccination against COVID-19 are both influenced by patients’ health status and involve a systemic physiological response. In view of the systemic function of endocrine hormones, endocrine disorders themselves and the therapeutics used to treat them can influence the outcomes of vaccination for COVID-19. However, there are very limited data to support the development of clinical guidelines for patients with specific medical backgrounds based on large clinical trials. In the current severe circumstances of the COVID-19 pandemic, position statements made by clinical specialists are essential to provide appropriate recommendations based on both medical evidence and clinical experiences. As endocrinologists, we would like to present the medical background of COVID-19 vaccination, as well as precautions to prevent the side effects of COVID-19 vaccination in patients with specific endocrine disorders, including adrenal insufficiency, diabetes mellitus, osteoporosis, autoimmune thyroid disease, hypogonadism, and pituitary disorders.
-
Citations
Citations to this article as recorded by
- COVID-19 mRNA vaccine may trigger subacute thyroiditis
Mehmet Sözen, Ömercan Topaloğlu, Berrin Çetinarslan, Alev Selek, Zeynep Cantürk, Emre Gezer, Damla Köksalan, Taner Bayraktaroğlu Human Vaccines & Immunotherapeutics.2024; 17(12): 5120. CrossRef - The role of co-morbidities in the development of an AEFI after COVID-19 vaccination in a large prospective cohort with patient-reported outcomes in the Netherlands
C. Ouaddouh, J.W. Duijster, T. Lieber, F.P.A.M. van Hunsel Expert Opinion on Drug Safety.2024; 23(3): 323. CrossRef - Thyroid dysfunction in COVID-19
David Tak Wai Lui, Chi Ho Lee, Yu Cho Woo, Ivan Fan Ngai Hung, Karen Siu Ling Lam Nature Reviews Endocrinology.2024; 20(6): 336. CrossRef - Adult-Onset Type 1 Diabetes Development Following COVID-19 mRNA Vaccination
Hyeyeon Moon, Sunghwan Suh, Mi Kyoung Park Journal of Korean Medical Science.2023;[Epub] CrossRef - Prior immunization status of COVID-19 patients and disease severity: A multicenter retrospective cohort study assessing the different types of immunity
Javaria Aslam, Faisal Shahzad Khan, Muhammad Talha Haris, Hewad Hewadmal, Maryam Khalid, Mohammad Y. Alshahrani, Qurrat-ul-ain Aslam, Irrum Aneela, Urooj Zafar Vaccine.2023; 41(2): 598. CrossRef - Mortality and Severity of Coronavirus Disease 2019 in Patients with Long-Term Glucocorticoid Therapy: A Korean Nationwide Cohort Study
Eu Jeong Ku, Keeho Song, Kyoung Min Kim, Gi Hyeon Seo, Soon Jib Yoo Endocrinology and Metabolism.2023; 38(2): 253. CrossRef - Pituitary Diseases and COVID-19 Outcomes in South Korea: A Nationwide Cohort Study
Jeonghoon Ha, Kyoung Min Kim, Dong-Jun Lim, Keeho Song, Gi Hyeon Seo Journal of Clinical Medicine.2023; 12(14): 4799. CrossRef - Inactivated SARS-CoV-2 vaccination does not disturb the clinical course of Graves’ disease: An observational cohort study
Shichen Xu, Huixin Yu, Xian Cheng, Jing Wu, Jiandong Bao, Li Zhang Vaccine.2023; 41(38): 5648. CrossRef - Adrenal Crisis Associated With COVID-19 Vaccination in Patients With Adrenal Insufficiency
Yukako Kurematsu, Takako Mohri, Sadanori Okada, Yutaka Takahashi JCEM Case Reports.2023;[Epub] CrossRef - Adverse Events Associated with COVID-19 Vaccination in Adolescents with Endocrinological Disorders: A Cross-Sectional Study
İbrahim Mert Erbaş, İrem Ceren Erbaş, Gözde Akın Kağızmanlı, Kübra Yüksek Acinikli, Özge Besci, Korcan Demir, Ece Böber, Nurşen Belet, Ayhan Abacı Journal of Clinical Research in Pediatric Endocrinology.2023; 15(3): 248. CrossRef - Neue Aspekte der Glukokortikoidsubstitution bei Nebennierenrindeninsuffizienz
Tina Kienitz, Gesine Meyer Der Internist.2022; 63(1): 12. CrossRef - Endocrine Follow-up During Post-Acute COVID-19: Practical Recommendations Based on Available Clinical Evidence
Rimesh Pal, Ameya Joshi, Sanjay K. Bhadada, Mainak Banerjee, Suresh Vaikkakara, Satinath Mukhopadhyay Endocrine Practice.2022; 28(4): 425. CrossRef - Safety of Inactivated and mRNA COVID-19 Vaccination Among Patients Treated for Hypothyroidism: A Population-Based Cohort Study
Xi Xiong, Carlos King Ho Wong, Ivan Chi Ho Au, Francisco Tsz Tsun Lai, Xue Li, Eric Yuk Fai Wan, Celine Sze Ling Chui, Esther Wai Yin Chan, Franco Wing Tak Cheng, Kristy Tsz Kwan Lau, Chi Ho Lee, Yu Cho Woo, David Tak Wai Lui, Ian Chi Kei Wong Thyroid.2022; 32(5): 505. CrossRef - The New Entity of Subacute Thyroiditis amid the COVID-19 Pandemic: From Infection to Vaccine
Mihaela Popescu, Adina Ghemigian, Corina Maria Vasile, Andrei Costache, Mara Carsote, Alice Elena Ghenea Diagnostics.2022; 12(4): 960. CrossRef - Adrenal Crisis Secondary to COVID-19 Vaccination in a Patient With Hypopituitarism
Nikolina Markovic, Anila Faizan, Chirag Boradia, Sridhar Nambi AACE Clinical Case Reports.2022; 8(4): 171. CrossRef - The Effect of Inactivated SARS-CoV-2 Vaccines on TRAB in Graves’ Disease
LingHong Huang, ZhengRong Jiang, JingXiong Zhou, YuPing Chen, HuiBin Huang Frontiers in Endocrinology.2022;[Epub] CrossRef - Osteoporosis in Patients With Respiratory Diseases
Yue Ma, Shui Qiu, Renyi Zhou Frontiers in Physiology.2022;[Epub] CrossRef - Pilot Findings on SARS-CoV-2 Vaccine-Induced Pituitary Diseases: A Mini Review from Diagnosis to Pathophysiology
Ach Taieb, El Euch Mounira Vaccines.2022; 10(12): 2004. CrossRef - Forty Years Together, New Leap Forward! The 40th Anniversary of the Korean Endocrine Society
Jong Chul Won, Ki-Hyun Baek Endocrinology and Metabolism.2022; 37(6): 851. CrossRef - No need of glucocorticoid dose adjustment in patients with adrenal insufficiency before COVID-19 vaccine
Tania Pilli, Cristina Dalmiglio, Gilda Dalmazio, Alfonso Sagnella, Raffaella Forleo, Lucia Brilli, Fabio Maino, Cristina Ciuoli, Maria Grazia Castagna European Journal of Endocrinology.2022; 187(1): K7. CrossRef - Diabetes and COVID-19 Vaccination
Hae Dong Choi, Jun Sung Moon The Journal of Korean Diabetes.2021; 22(4): 221. CrossRef
- Thyroid
- A Multicenter, Randomized, Controlled Trial for Assessing the Usefulness of Suppressing Thyroid Stimulating Hormone Target Levels after Thyroid Lobectomy in Low to Intermediate Risk Thyroid Cancer Patients (MASTER): A Study Protocol
-
Eun Kyung Lee, Yea Eun Kang, Young Joo Park, Bon Seok Koo, Ki-Wook Chung, Eu Jeong Ku, Ho-Ryun Won, Won Sang Yoo, Eonju Jeon, Se Hyun Paek, Yong Sang Lee, Dong Mee Lim, Yong Joon Suh, Ha Kyoung Park, Hyo-Jeong Kim, Bo Hyun Kim, Mijin Kim, Sun Wook Kim, Ka Hee Yi, Sue K. Park, Eun-Jae Jung, June Young Choi, Ja Seong Bae, Joon Hwa Hong, Kee-Hyun Nam, Young Ki Lee, Hyeong Won Yu, Sujeong Go, Young Mi Kang, MASTER study group
-
Endocrinol Metab. 2021;36(3):574-581. Published online May 26, 2021
-
DOI: https://doi.org/10.3803/EnM.2020.943
-
-
7,249
View
-
295
Download
-
11
Web of Science
-
14
Crossref
-
Abstract
PDFPubReader ePub
- Background
Postoperative thyroid stimulating hormone (TSH) suppression therapy is recommended for patients with intermediate- and high-risk differentiated thyroid cancer to prevent the recurrence of thyroid cancer. With the recent increase in small thyroid cancer cases, the extent of resection during surgery has generally decreased. Therefore, questions have been raised about the efficacy and long-term side effects of TSH suppression therapy in patients who have undergone a lobectomy.
Methods This is a multicenter, prospective, randomized, controlled clinical trial in which 2,986 patients with papillary thyroid cancer are randomized into a high-TSH group (intervention) and a low-TSH group (control) after having undergone a lobectomy. The principle of treatment includes a TSH-lowering regimen aimed at TSH levels between 0.3 and 1.99 μIU/mL in the low-TSH group. The high-TSH group targets TSH levels between 2.0 and 7.99 μIU/mL. The dose of levothyroxine will be adjusted at each visit to maintain the target TSH level. The primary outcome is recurrence-free survival, as assessed by neck ultrasound every 6 to 12 months. Secondary endpoints include disease-free survival, overall survival, success rate in reaching the TSH target range, the proportion of patients with major cardiovascular diseases or bone metabolic disease, the quality of life, and medical costs. The follow-up period is 5 years.
Conclusion The results of this trial will contribute to establishing the optimal indication for TSH suppression therapy in low-risk papillary thyroid cancer patients by evaluating the benefit and harm of lowering TSH levels in terms of recurrence, metabolic complications, costs, and quality of life.
-
Citations
Citations to this article as recorded by
- Effect of thyroid-stimulating hormone suppression on quality of life in thyroid lobectomy patients: interim analysis of a multicenter, randomized controlled trial in low- to intermediate-risk thyroid cancer patients (MASTER study)
Ja Kyung Lee, Eu Jeong Ku, Su-jin Kim, Woochul Kim, Jae Won Cho, Kyong Yeun Jung, Hyeong Won Yu, Yea Eun Kang, Mijin Kim, Hee Kyung Kim, Junsun Ryu, June Young Choi Annals of Surgical Treatment and Research.2024; 106(1): 19. CrossRef - Clinical impact of coexistent chronic lymphocytic thyroiditis on central lymph node metastasis in low- to intermediate-risk papillary thyroid carcinoma: The MASTER study
Da Beom Heo, Ho-Ryun Won, Kyung Tae, Yea Eun Kang, Eonju Jeon, Yong Bae Ji, Jae Won Chang, June Young Choi, Hyeong Won Yu, Eu Jeong Ku, Eun Kyung Lee, Mijin Kim, Jun-Ho Choe, Bon Seok Koo Surgery.2024; 175(4): 1049. CrossRef - Dynamic Changes in Treatment Response af-ter 131I in Differentiated Thyroid Cancer and Their Relationship with Recurrence Risk Stratification and TNM Staging
璐 狄 Advances in Clinical Medicine.2024; 14(03): 1083. CrossRef - Korean Thyroid Association Guidelines on the Management of Differentiated Thyroid Cancers; Part II. Follow-up Surveillance after Initial Treatment 2024
Mijin Kim, Ji-In Bang, Ho-Cheol Kang, Sun Wook Kim, Dong Gyu Na, Young Joo Park, Youngduk Seo, Young Shin Song, So Won Oh, Sang-Woo Lee, Eun Kyung Lee, Ji Ye Lee, Dong-Jun Lim, Ari Chong, Yun Jae Chung, Chae Moon Hong, Min Kyoung Lee, Bo Hyun Kim International Journal of Thyroidology.2024; 17(1): 115. CrossRef - Levothyroxine Dosage and the Increased Risk of Second Primary Malignancy in Thyroid Cancer Survivors
Young Joo Park Clinical Thyroidology®.2024; 36(7): 258. CrossRef - Prognostic Implications of Maintaining the Target Thyroid-Stimulating Hormone Status Based on the 2015 American Thyroid Association Guidelines in Patients with Low-Risk Papillary Thyroid Carcinoma after Lobectomy: A 5-Year Landmark Analysis
Ye Won Jeon, Young Jin Suh, Seung Taek Lim Cancers.2024; 16(19): 3253. CrossRef - ASO Author Reflections: Active Surveillance may be Possible in Patients with T1b Papillary Thyroid Carcinoma Over 55 Years of Age Without High-Risk Features on Preoperative Examinations
Ho-Ryun Won, Eonju Jeon, Da Beom Heo, Jae Won Chang, Minho Shong, Je Ryong Kim, Hyemi Ko, Yea Eun Kang, Hyon-Seung Yi, Ju Hee Lee, Kyong Hye Joung, Ji Min Kim, Younju Lee, Sung-Woo Kim, Young Ju Jeong, Yong Bae Ji, Kyung Tae, Bon Seok Koo Annals of Surgical Oncology.2023; 30(4): 2254. CrossRef - Outcomes and Trends of Treatments in High‐Risk Differentiated Thyroid Cancer
Arash Abiri, Khodayar Goshtasbi, Sina J. Torabi, Edward C. Kuan, William B. Armstrong, Tjoson Tjoa, Yarah M. Haidar Otolaryngology–Head and Neck Surgery.2023; 168(4): 745. CrossRef - Current Controversies in Low-Risk Differentiated Thyroid Cancer: Reducing Overtreatment in an Era of Overdiagnosis
Timothy M Ullmann, Maria Papaleontiou, Julie Ann Sosa The Journal of Clinical Endocrinology & Metabolism.2023; 108(2): 271. CrossRef - Age-Dependent Clinicopathological Characteristics of Patients with T1b Papillary Thyroid Carcinoma: Implications for the Possibility of Active Surveillance
Ho-Ryun Won, Eonju Jeon, Da Beom Heo, Jae Won Chang, Minho Shong, Je Ryong Kim, Hyemi Ko, Yea Eun Kang, Hyon-Seung Yi, Ju Hee Lee, Kyong Hye Joung, Ji Min Kim, Younju Lee, Sung-Woo Kim, Young Ju Jeong, Yong Bae Ji, Kyung Tae, Bon Seok Koo Annals of Surgical Oncology.2023; 30(4): 2246. CrossRef - Potential impact of obesity on the aggressiveness of low- to intermediate-risk papillary thyroid carcinoma: results from a MASTER cohort study
Mijin Kim, Yae Eun Kang, Young Joo Park, Bon Seok Koo, Eu Jeong Ku, June Young Choi, Eun Kyung Lee, Bo Hyun Kim Endocrine.2023; 82(1): 134. CrossRef - Differentiated thyroid cancer: a focus on post-operative thyroid hormone replacement and thyrotropin suppression therapy
Benjamin J. Gigliotti, Sina Jasim Endocrine.2023; 83(2): 251. CrossRef - Thyroid stimulating hormone suppression and recurrence after thyroid lobectomy for papillary thyroid carcinoma
Mi Rye Bae, Sung Hoon Nam, Jong-Lyel Roh, Seung-Ho Choi, Soon Yuhl Nam, Sang Yoon Kim Endocrine.2022; 75(2): 487. CrossRef - The Concept of Economic Evaluation and Its Application in Thyroid Cancer Research
Kyungsik Kim, Mijin Kim, Woojin Lim, Bo Hyun Kim, Sue K. Park Endocrinology and Metabolism.2021; 36(4): 725. CrossRef
- Clinical Study
- Changes in Glucose Metabolism after Adrenalectomy or Treatment with a Mineralocorticoid Receptor Antagonist for Primary Aldosteronism
-
Yu-Fang Lin, Kang-Yung Peng, Chia-Hui Chang, Ya-Hui Hu, Vin-Cent Wu, Shiu-Dong Chung, Taiwan Primary Aldosteronism Investigation (TAIPAI) Study Group
-
Endocrinol Metab. 2020;35(4):838-846. Published online December 2, 2020
-
DOI: https://doi.org/10.3803/EnM.2020.797
-
-
6,009
View
-
133
Download
-
8
Web of Science
-
8
Crossref
-
Abstract
PDFPubReader ePub
- Background
Data on the effects of excess aldosterone on glucose metabolism are inconsistent. This study compared the changes in glucose metabolism in patients with primary aldosteronism (PA) after adrenalectomy or treatment with a mineralocorticoid receptor antagonist (MRA).
Methods Overall, 241 patients were enrolled; 153 underwent adrenalectomy and 88 received an MRA. Fasting glucose, homeostatic model assessment of insulin resistance (HOMA-IR), and homeostatic model assessment of β-cell function (HOMA-β) were compared between the treatment groups after 1 year. Plasma aldosterone concentration (PAC) and factors determining HOMA-IR and PAC were evaluated.
Results No baseline differences were observed between the groups. Fasting insulin, HOMA-IR, and HOMA-β increased in both groups and there were no significant differences in fasting glucose following treatment. Multiple regression analysis showed associations between PAC and HOMA-IR (β=0.172, P=0.017) after treatment. Treatment with spironolactone was the only risk factor associated with PAC >30 ng/dL (odds ratio, 5.2; 95% confidence interval [CI], 2.7 to 10; P<0.001) and conferred a 2.48-fold risk of insulin resistance after 1 year compared with surgery (95% CI, 1.3 to 4.8; P=0.007).
Conclusion Spironolactone treatment might increase insulin resistance in patients with PA. This strengthened the current recommendation that adrenalectomy is the preferred strategy for patient with positive lateralization test. Achieving a post-treatment PAC of <30 ng/dL for improved insulin sensitivity may be appropriate.
-
Citations
Citations to this article as recorded by
- How should anti-hypertensive medications be adjusted before screening for primary aldosteronism?
Jin-Ying Lu, Yi-Yao Chang, Ting-Wei Lee, Ming-Hsien Wu, Zheng-Wei Chen, Yen-Ta Huang, Tai-Shuan Lai, Leay Kiaw Er, Yen-Hung Lin, Vin-Cent Wu, Hao-Min Cheng, Hsien-Li Kao, Charles Jia-Yin Hou, Kwan-Dun Wu, Szu-Tah Chen, Feng-Hsuan Liu Journal of the Formosan Medical Association.2024; 123: S91. CrossRef - Diabete e sindrome metabolica nel paziente con iperaldosteronismo primario
Stella Bernardi, Valerio Velardi, Federica De Luca, Giulia Zuolo, Veronica Calabrò, Riccardo Candido, Bruno Fabris L'Endocrinologo.2024; 25(1): 48. CrossRef - Prevalence, risk factors and evolution of diabetes mellitus after treatment in primary aldosteronism. Results from the SPAIN-ALDO registry
M. Araujo-Castro, M. Paja Fano, B. Pla Peris, M. González Boillos, E. Pascual-Corrales, A. M. García Cano, P. Parra Ramírez, P. Martín Rojas-Marcos, J. G. Ruiz-Sanchez, A. Vicente Delgado, E. Gómez Hoyos, R. Ferreira, I. García Sanz, M. Recasens Sala, R. Journal of Endocrinological Investigation.2023; 46(11): 2343. CrossRef - Estimated glomerular filtration rate-dip after medical target therapy associated with increased mortality and cardiovascular events in patients with primary aldosteronism
Jia-Yuh Sheu, Shuo-Meng Wang, Vin-Cent Wu, Kuo-How Huang, Chi-Shin Tseng, Yuan-Ju Lee, Yao-Chou Tsai, Yen-Hung Lin, Jeff S. Chueh Journal of Hypertension.2023; 41(9): 1401. CrossRef - Risk of dementia in primary aldosteronism compared with essential hypertension: a nationwide cohort study
Namki Hong, Kyoung Jin Kim, Min Heui Yu, Seong Ho Jeong, Seunghyun Lee, Jung Soo Lim, Yumie Rhee Alzheimer's Research & Therapy.2023;[Epub] CrossRef - Secondary diabetes mellitus due to primary aldosteronism
Melpomeni Moustaki, Stavroula A. Paschou, Eleni C. Vakali, Andromachi Vryonidou Endocrine.2022; 79(1): 17. CrossRef - Serum Cystatin C Levels Could Predict Rapid Kidney Function Decline in A Community-Based Population
Wei-Ching Fang, Hsing-Yu Chen, Shao-Chi Chu, Po-Hsi Wang, Chin-Chan Lee, I-Wen Wu, Chiao-Yin Sun, Heng-Jung Hsu, Chun-Yu Chen, Yung-Chang Chen, Vin-Cent Wu, Heng-Chih Pan Biomedicines.2022; 10(11): 2789. CrossRef - Recovery from diabetes mellitus in primary aldosteronism patients after adrenalectomy
Yu Liu, Lede Lin, Chi Yuan, Sikui Shen, Yin Tang, Zhihong Liu, Yuchun Zhu, Liang Zhou BMC Endocrine Disorders.2022;[Epub] CrossRef
- Adrenal gland
- Primary Aldosteronism and Cerebrovascular Diseases
-
Zheng-Wei Chen, Chi-Sheng Hung, Vin-Cent Wu, Yen-Hung Lin
-
Endocrinol Metab. 2018;33(4):429-434. Published online November 30, 2018
-
DOI: https://doi.org/10.3803/EnM.2018.33.4.429
-
-
5,476
View
-
69
Download
-
21
Web of Science
-
20
Crossref
-
Abstract
PDFPubReader ePub
As diagnostic techniques have advanced, primary aldosteronism (PA) has emerged as the most common cause of secondary hypertension. The excess of aldosterone caused by PA resulted in not only cardiovascular complications, including coronary artery disease, myocardial infarction, arrhythmia, and heart failure, but also cerebrovascular complications, such as stroke and transient ischemic attack. Moreover, PA is associated more closely with these conditions than is essential hypertension. In this review, we present up-to-date findings on the association between PA and cerebrovascular diseases.
-
Citations
Citations to this article as recorded by
- Aldosterone and aldosterone synthase inhibitors in cardiorenal disease
Subodh Verma, Avinash Pandey, Arjun K. Pandey, Javed Butler, John S. Lee, Hwee Teoh, C. David Mazer, Mikhail N. Kosiborod, Francesco Cosentino, Stefan D. Anker, Kim A. Connelly, Deepak L. Bhatt American Journal of Physiology-Heart and Circulatory Physiology.2024; 326(3): H670. CrossRef - Cardiovascular and metabolic characters of KCNJ5 somatic mutations in primary aldosteronism
Yi-Yao Chang, Bo-Ching Lee, Zheng-Wei Chen, Cheng-Hsuan Tsai, Chin-Chen Chang, Che-Wei Liao, Chien-Ting Pan, Kang-Yung Peng, Chia-Hung Chou, Ching-Chu Lu, Vin-Cent Wu, Chi-Sheng Hung, Yen-Hung Lin Frontiers in Endocrinology.2023;[Epub] CrossRef - Risk of dementia in primary aldosteronism compared with essential hypertension: a nationwide cohort study
Namki Hong, Kyoung Jin Kim, Min Heui Yu, Seong Ho Jeong, Seunghyun Lee, Jung Soo Lim, Yumie Rhee Alzheimer's Research & Therapy.2023;[Epub] CrossRef - Study on the Association between Primary Aldosteronism and Cerebrovascular Disease
·阿卜杜克热木 阿依努尔 Advances in Clinical Medicine.2023; 13(10): 16819. CrossRef - Anticoagulant therapy in patients with atrial fibrillation and chronic kidney disease: Arguments for or against
A. G. Komarova, N. L. Lyakhova, S. D. Covantsev, E. A. Naryshkina, D. V. Slepukhova Medical alphabet.2023; (25): 14. CrossRef - Association of Dip in eGFR With Clinical Outcomes in Unilateral Primary Aldosteronism Patients After Adrenalectomy
Jui-Yi Chen, Kuo-How Huang, Yen-Hung Lin, Jeff S Chueh, Hsien-Yi Wang, Vin-Cent Wu The Journal of Clinical Endocrinology & Metabolism.2023;[Epub] CrossRef - Hypertension outcomes of adrenalectomy for unilateral primary aldosteronism
Igor Hartmann, Frantisek Hruska, Jan Vaclavik, Eva Kocianova, Zdenek Frysak, Marika Nesvadbova, Zbynek Tudos, Filip Ctvrtlik, Klara Benesova Endocrine.2022; 76(1): 142. CrossRef - Cerebro-Cardiovascular Risk, Target Organ Damage, and Treatment Outcomes in Primary Aldosteronism
Xiao Lin, Muhammad Hasnain Ehsan Ullah, Xiong Wu, Feng Xu, Su-Kang Shan, Li-Min Lei, Ling-Qing Yuan, Jun Liu Frontiers in Cardiovascular Medicine.2022;[Epub] CrossRef - Primary Aldosteronism More Prevalent in Patients With Cardioembolic Stroke and Atrial Fibrillation
Van Nguyen, Tian Ming Tu, Marlie Jane B. Mamauag, Jovan Lai, Seyed Ehsan Saffari, Tar Choon Aw, Lizhen Ong, Roger S. Y. Foo, Siang Chew Chai, Shaun Fones, Meifen Zhang, Troy H. Puar Frontiers in Endocrinology.2022;[Epub] CrossRef - Implication of MR Activity in Posttreatment Arterial Stiffness Reversal in Patients With Primary Aldosteronism
Zheng-Wei Chen, Chien-Ting Pan, Che-Wei Liao, Cheng-Hsuan Tsai, Yi-Yao Chang, Chin-Chen Chang, Bo-Ching Lee, Yu-Wei Chiu, Wei-Chieh Huang, Shuo-Meng Wang, Ching-Chu Lu, Jeff S Chueh, Vin-Cent Wu, Chi-Sheng Hung, Yen-Hung Lin The Journal of Clinical Endocrinology & Metabolism.2022;[Epub] CrossRef - Time-Dependent Risk of Atrial Fibrillation in Patients With Primary Aldosteronism After Medical or Surgical Treatment Initiation
Kyoung Jin Kim, Namki Hong, Min Heui Yu, Hokyou Lee, Seunghyun Lee, Jung Soo Lim, Yumie Rhee Hypertension.2021; 77(6): 1964. CrossRef - Pearls & Oy-sters: Cerebral Microbleeds Caused by Adrenocortical Adenoma-Related Primary Aldosteronism
Sun Min Lee, Yong Jun Choi, Kihwang Lee, Hyeung Kyoo Kim, Jin-Sun Park, Yong Cheol Lim, Jang-Hee Kim, So Young Moon Neurology.2021; 96(20): 960. CrossRef - Cellular Senescence in Human Aldosterone-Producing Adrenocortical Cells and Related Disorders
Jacopo Pieroni, Yuto Yamazaki, Xin Gao, Yuta Tezuka, Hiroko Ogata, Kei Omata, Yoshikiyo Ono, Ryo Morimoto, Yasuhiro Nakamura, Fumitoshi Satoh, Hironobu Sasano Biomedicines.2021; 9(5): 567. CrossRef - Contralateral Suppression at Adrenal Venous Sampling Is Associated with Renal Impairment Following Adrenalectomy for Unilateral Primary Aldosteronism
Ye Seul Yang, Seung Hun Lee, Jung Hee Kim, Jee Hee Yoo, Jung Hyun Lee, Seo Young Lee, A Ram Hong, Dong-Hwa Lee, Jung-Min Koh, Jae Hyeon Kim, Sang Wan Kim Endocrinology and Metabolism.2021; 36(4): 875. CrossRef - Aldosterone Inhibits In Vitro Myogenesis by Increasing Intracellular Oxidative Stress via Mineralocorticoid Receptor
Jin Young Lee, Da Ae Kim, Eunah Choi, Yun Sun Lee, So Jeong Park, Beom-Jun Kim Endocrinology and Metabolism.2021; 36(4): 865. CrossRef - Heart-Ankle Pulse Wave Velocity Is Superior to Brachial-Ankle Pulse Wave Velocity in Detecting Aldosterone-Induced Arterial Stiffness
Zheng-Wei Chen, Chien-Ting Pan, Cheng-Hsuan Tsai, Yi-Yao Chang, Chin-Chen Chang, Bo-Ching Lee, Yu-Wei Chiu, Wei-Chieh Huang, Yu-Li Lin, Vin-Cent Wu, Chi-Sheng Hung, Che-Wei Liao, Yen-Hung Lin Biomedicines.2021; 9(10): 1285. CrossRef - Effects of nimodipine combined with betahistine on CRP and other inflammatory cytokines and vascular endothelial function in patients with hypertensive cerebral vasospasm
Xuanwei Liu, Na’na Zhao, Kexue Zeng, Peng Xiao, Pengjie Sheng, Xun Luo, Yulong Wang Clinical Hemorheology and Microcirculation.2020; 75(3): 279. CrossRef - Associations between primary aldosteronism and diabetes, poor bone health, and sleep apnea—what do we know so far?
Huai Heng Loh, Norlela Sukor Journal of Human Hypertension.2020; 34(1): 5. CrossRef - Predicting factors related with uncured hypertension after retroperitoneal laparoscopic adrenalectomy for unilateral primary aldosteronism
WuYun BiLiGe, Chaoqi Wang, JiRiGaLa Bao, Dahai Yu, A Min, Zhi Hong, Xiangbao Chen, Min Wang, Dongmei Wang Medicine.2019; 98(30): e16611. CrossRef - Surgical Approach to Endocrine Hypertension in Patients with Adrenal Disorders
Jessica Shank, Jason D. Prescott, Aarti Mathur Endocrinology and Metabolism Clinics of North America.2019; 48(4): 875. CrossRef
- Clinical Study
- Disease-Specific Mortality of Differentiated Thyroid Cancer Patients in Korea: A Multicenter Cohort Study
-
Min Ji Jeon, Won Gu Kim, Tae Hyuk Kim, Hee Kyung Kim, Bo Hyun Kim, Hyon-Seung Yi, Eun Sook Kim, Hosu Kim, Young Nam Kim, Eun Heui Kim, Tae Yong Kim, Sun Wook Kim, Ho-Cheol Kang, Jae Hoon Chung, Young Kee Shong, Won Bae Kim
-
Endocrinol Metab. 2017;32(4):434-441. Published online November 22, 2017
-
DOI: https://doi.org/10.3803/EnM.2017.32.4.434
-
-
6,346
View
-
54
Download
-
30
Web of Science
-
27
Crossref
-
Abstract
PDFSupplementary MaterialPubReader
- Background
Little is known regarding disease-specific mortality of differentiated thyroid cancer (DTC) patients and its risk factors in Korea. MethodsWe retrospectively reviewed a large multi-center cohort of thyroid cancer from six Korean hospitals and included 8,058 DTC patients who underwent initial surgery between 1996 and 2005. ResultsMean age of patients at diagnosis was 46.2±12.3 years; 87% were females. Most patients had papillary thyroid cancer (PTC; 97%) and underwent total thyroidectomy (85%). Mean size of the primary tumor was 1.6±1.0 cm. Approximately 40% of patients had cervical lymph node (LN) metastases and 1.3% had synchronous distant metastases. During 11.3 years of follow-up, 150 disease-specific mortalities (1.9%) occurred; the 10-year disease-specific survival (DSS) rate was 98%. According to the year of diagnosis, the number of disease-specific mortality was not different. However, the rate of disease-specific mortality decreased during the study period (from 7.7% to 0.7%). Older age (≥45 years) at diagnosis, male, follicular thyroid cancer (FTC) versus PTC, larger tumor size (>2 cm), presence of extrathyroidal extension (ETE), lateral cervical LN metastasis, distant metastasis and tumor node metastasis (TNM) stage were independent risk factors of disease-specific mortality of DTC patients. ConclusionThe rate of disease-specific mortality of Korean DTC patients was 1.9%; the 10-year DSS rate was 98% during 1996 to 2005. Older age at diagnosis, male, FTC, larger tumor size, presence of ETE, lateral cervical LN metastasis, distant metastasis, and TNM stages were significant risk factors of disease-specific mortality of Korean DTC patients.
-
Citations
Citations to this article as recorded by
- Impact of Tumor Size on Prognosis in Differentiated Thyroid Cancer with Gross Extrathyroidal Extension to Strap Muscles: Redefining T3b
Joonseon Park, Solji An, Ja Seong Bae, Kwangsoon Kim, Jeong Soo Kim Cancers.2024; 16(14): 2577. CrossRef - Log odds of negative lymph nodes/T stage ratio (LONT): A new prognostic tool for differentiated thyroid cancer without metastases in patients aged 55 and older
Xuezhen Wang, Yufan Wu, Xiaoxia Li, Jinsheng Hong, Mingwei Zhang Frontiers in Endocrinology.2023;[Epub] CrossRef - The association between vitamin D supplementation and the long-term prognosis of differentiated thyroid cancer patients: a retrospective observational cohort study with propensity score matching
Jong-hyuk Ahn, Hoonsung Choi, Su-jin Kim, Sun Wook Cho, Kyu Eun Lee, Do Joon Park, Young Joo Park Frontiers in Endocrinology.2023;[Epub] CrossRef - Linear association between radioactive iodine dose and second primary malignancy risk in thyroid cancer
Kyeong Jin Kim, Kyoung Jin Kim, Jimi Choi, Nam Hoon Kim, Sin Gon Kim JNCI: Journal of the National Cancer Institute.2023; 115(6): 695. CrossRef - Outcomes of Advanced Medullary Thyroid Carcinoma in the Era of Targeted Therapy
Nicholas L. Kesby, Alexander J. Papachristos, Matti Gild, Ahmad Aniss, Mark S. Sywak, Roderick Clifton-Bligh, Stan B. Sidhu, Anthony R. Glover Annals of Surgical Oncology.2022; 29(1): 64. CrossRef - Clinical Implication of Mutifocality for Risk of Recurrence in Patients With Papillary Thyroid Carcinoma
Kwangsoon Kim, Ja Seong Bae, Jeong Soo Kim Journal of Endocrine Surgery.2022; 22(1): 10. CrossRef - Clinical Factors Predictive of Lymph Node Metastasis in Thyroid Cancer Patients: A Multivariate Analysis
Hui Zheng, Victoria Lai, Jana Lu, Jin K Kang, Jiling Chou, Kenneth D Burman, Leonard Wartofsky, Jennifer E Rosen Journal of the American College of Surgeons.2022; 234(4): 691. CrossRef - Minimal extrathyroidal extension is associated with lymph node metastasis in single papillary thyroid microcarcinoma: a retrospective analysis of 814 patients
Ra-Yeong Song, Hee Sung Kim, Kyung Ho Kang World Journal of Surgical Oncology.2022;[Epub] CrossRef - Central Lymph Node Ratio Predicts Recurrence in Patients with N1b Papillary Thyroid Carcinoma
Il Ku Kang, Kwangsoon Kim, Joonseon Park, Ja Seong Bae, Jeong Soo Kim Cancers.2022; 14(15): 3677. CrossRef - Characterization of the CpG island methylator phenotype subclass in papillary thyroid carcinoma
Pengfei Gu, Yu Zeng, Weike Ma, Wei Zhang, Yu Liu, Fengli Guo, Xianhui Ruan, Jiadong Chi, Xiangqian Zheng, Ming Gao Frontiers in Endocrinology.2022;[Epub] CrossRef - MicroRNA Profile for Diagnostic and Prognostic Biomarkers in Thyroid Cancer
Jong-Lyul Park, Seon-Kyu Kim, Sora Jeon, Chan-Kwon Jung, Yong-Sung Kim Cancers.2021; 13(4): 632. CrossRef - Lactate Dehydrogenase A as a Potential New Biomarker for Thyroid Cancer
Eun Jeong Ban, Daham Kim, Jin Kyong Kim, Sang-Wook Kang, Jandee Lee, Jong Ju Jeong, Kee-Hyun Nam, Woong Youn Chung, Kunhong Kim Endocrinology and Metabolism.2021; 36(1): 96. CrossRef - Male sex is not an independent risk factor for recurrence of differentiated thyroid cancer: a propensity score-matching study
Joonseon Park, Kwangsoon Kim, Dong-Jun Lim, Ja Seong Bae, Jeong Soo Kim Scientific Reports.2021;[Epub] CrossRef - A Newly Developed Pancreatic Adenocarcinoma in a Patient with Advanced Thyroid Cancer under Long-Term Sorafenib Use
Min Ji Kim, Han-Sang Baek, Sung Hak Lee, Dong-Jun Lim International Journal of Thyroidology.2021; 14(2): 175. CrossRef - Modified risk stratification based on cervical lymph node metastases following lobectomy for papillary thyroid carcinoma
Eyun Song, Jonghwa Ahn, Dong Eun Song, Won Woong Kim, Min Ji Jeon, Tae‐Yon Sung, Tae Yong Kim, Ki Wook Chung, Won Bae Kim, Young Kee Shong, Suck Joon Hong, Yu‐Mi Lee, Won Gu Kim Clinical Endocrinology.2020; 92(4): 358. CrossRef - Long-term scintigraphic and clinical follow up in patients with differentiated thyroid cancer and iodine avid bone metastases
Omnia Mohamed Talaat, Ismail Mohamed Ali, Sherif Maher Abolyazid, Bader Abdelmaksoud, Ibrahim Mansour Nasr Nuclear Medicine Communications.2020; 41(4): 327. CrossRef - Highly prevalent BRAF V600E and low-frequency TERT promoter mutations underlie papillary thyroid carcinoma in Koreans
Sue Youn Kim, Taeeun Kim, Kwangsoon Kim, Ja Seong Bae, Jeong Soo Kim, Chan Kwon Jung Journal of Pathology and Translational Medicine.2020; 54(4): 310. CrossRef - Clinical Implication of World Health Organization Classification in Patients with Follicular Thyroid Carcinoma in South Korea: A Multicenter Cohort Study
Meihua Jin, Eun Sook Kim, Bo Hyun Kim, Hee Kyung Kim, Hyon-Seung Yi, Min Ji Jeon, Tae Yong Kim, Ho-Cheol Kang, Won Bae Kim, Young Kee Shong, Mijin Kim, Won Gu Kim Endocrinology and Metabolism.2020; 35(3): 618. CrossRef - The age threshold of the 8th edition AJCC classification is useful for indicating patients with aggressive papillary thyroid cancer in clinical practice
Krzysztof Kaliszewski, Dorota Diakowska, Łukasz Nowak, Beata Wojtczak, Jerzy Rudnicki BMC Cancer.2020;[Epub] CrossRef - Lobectomy Is Feasible for 1–4 cm Papillary Thyroid Carcinomas: A 10-Year Propensity Score Matched-Pair Analysis on Recurrence
Eyun Song, Minkyu Han, Hye-Seon Oh, Won Woong Kim, Min Ji Jeon, Yu-Mi Lee, Tae Yong Kim, Ki Wook Chung, Won Bae Kim, Young Kee Shong, Suck Joon Hong, Tae-Yon Sung, Won Gu Kim Thyroid.2019; 29(1): 64. CrossRef - The binary presence or absence of lymph node metastasis or extrathyroidal extension is not associated with survival in papillary thyroid cancers: Implications for staging systems
Hyun-Soo Zhang, Eun-Kyung Lee, Yuh-Seog Jung, Byung-Ho Nam, Boyoung Park Cancer Epidemiology.2019; 63: 101589. CrossRef - Risk of Adverse Obstetric Outcomes and the Abnormal Growth of Offspring in Women with a History of Thyroid Cancer
Geum Joon Cho, So-youn Kim, Hoi Chang Lee, Kyu-Min Lee, Sung Won Han, Min-Jeong Oh, Teresa K. Woodruff Thyroid.2019; 29(6): 879. CrossRef - Changes in Serum Thyroglobulin Levels After Lobectomy in Patients with Low-Risk Papillary Thyroid Cancer
Suyeon Park, Min Ji Jeon, Hye-Seon Oh, Yu-Mi Lee, Tae-Yon Sung, Minkyu Han, Ji Min Han, Tae Yong Kim, Ki-Wook Chung, Won Bae Kim, Young Kee Shong, Won Gu Kim Thyroid.2018; 28(8): 997. CrossRef - Clinical Outcomes of Differentiated Thyroid Cancer Patients with Local Recurrence or Distant Metastasis Detected in Old Age
Ji Min Han, Ji Cheol Bae, Hye In Kim, Sam Kwon, Min Ji Jeon, Won Gu Kim, Tae Yong Kim, Young Kee Shong, Won Bae Kim Endocrinology and Metabolism.2018; 33(4): 459. CrossRef - Prognosis of Differentiated Thyroid Carcinoma with Initial Distant Metastasis: A Multicenter Study in Korea
Hosu Kim, Hye In Kim, Sun Wook Kim, Jaehoon Jung, Min Ji Jeon, Won Gu Kim, Tae Yong Kim, Hee Kyung Kim, Ho-Cheol Kang, Ji Min Han, Yoon Young Cho, Tae Hyuk Kim, Jae Hoon Chung Endocrinology and Metabolism.2018; 33(2): 287. CrossRef - Decreasing Disease-Specific Mortality of Differentiated Thyroid Cancer in Korea: A Multicenter Cohort Study
Min Ji Jeon, Hee Kyung Kim, Eun Heui Kim, Eun Sook Kim, Hyon-Seung Yi, Tae Yong Kim, Ho-Cheol Kang, Young Kee Shong, Won Bae Kim, Bo Hyun Kim, Won Gu Kim Thyroid.2018; 28(9): 1121. CrossRef - Active Surveillance of Low-Risk Papillary Thyroid Microcarcinoma: A Multi-Center Cohort Study in Korea
Hye-Seon Oh, Jeonghoon Ha, Hye In Kim, Tae Hyuk Kim, Won Gu Kim, Dong-Jun Lim, Tae Yong Kim, Sun Wook Kim, Won Bae Kim, Young Kee Shong, Jae Hoon Chung, Jung Hwan Baek Thyroid.2018; 28(12): 1587. CrossRef
- Clinical Study
- Characteristics of Korean Patients with Primary Adrenal Insufficiency: A Registry-Based Nationwide Survey in Korea
-
A Ram Hong, Ohk-Hyun Ryu, Seong Yeon Kim, Sang Wan Kim
-
Endocrinol Metab. 2017;32(4):466-474. Published online December 14, 2017
-
DOI: https://doi.org/10.3803/EnM.2017.32.4.466
-
-
6,502
View
-
65
Download
-
14
Web of Science
-
12
Crossref
-
Abstract
PDFSupplementary MaterialPubReader
- Background
Primary adrenal insufficiency (PAI) is a rare, potentially life-threatening condition. There are few Korean studies on PAI, and most have had small sample sizes. We aimed to examine the etiology, clinical characteristics, treatment, and mortality of PAI in Korean patients. MethodsA nationwide, multicenter, registry-based survey was conducted to identify adults diagnosed with or treated for PAI at 30 secondary or tertiary care institutions in Korea between 2000 and 2014. ResultsA total of 269 patients with PAI were identified. The prevalence of PAI was 4.17 per million. The estimated incidence was 0.45 per million per year. The mean age at diagnosis was 49.0 years, and PAI was more prevalent in men. Adrenal tuberculosis was the most common cause of PAI in patients diagnosed before 2000; for those diagnosed thereafter, adrenal metastasis and tuberculosis were comparable leading causes. The etiology of PAI was not identified in 34.9% of cases. Of the patients receiving glucocorticoid replacement therapy, prednisolone was more frequently administered than hydrocortisone (69.4% vs. 26.5%, respectively), and only 27.1% of all patients received fludrocortisone. We observed an increased prevalence of metabolic disease and osteoporosis during the follow-up period (median, 60.2 months). The observed overall mortality and disease-specific mortality rates were 11.9% and 3.1%, respectively. ConclusionThe prevalence of PAI is significantly lower in Koreans than in reports from Western countries. The high frequency undetermined etiology in patients with PAI suggests the need to reveal accurate etiology of PAI in Korea.
-
Citations
Citations to this article as recorded by
- Genetic and phenotypic spectrum of non-21-hydroxylase-deficiency primary adrenal insufficiency in childhood: data from 111 Chinese patients
Ying Duan, Wanqi Zheng, Yu Xia, Huiwen Zhang, Lili Liang, Ruifang Wang, Yi Yang, Kaichuang Zhang, Deyun Lu, Yuning Sun, Lianshu Han, Yongguo Yu, Xuefan Gu, Yu Sun, Bing Xiao, Wenjuan Qiu Journal of Medical Genetics.2024; 61(1): 27. CrossRef - Approach to the Patient: Diagnosis of Primary Adrenal Insufficiency in Adults
Marianne Øksnes, Eystein S Husebye The Journal of Clinical Endocrinology & Metabolism.2023; 109(1): 269. CrossRef - Epidemiology and Causes of Primary Adrenal Insufficiency in Children: A Population-Based Study
Joonatan Borchers, Eero Pukkala, Outi Mäkitie, Saila Laakso The Journal of Clinical Endocrinology & Metabolism.2023; 108(11): 2879. CrossRef - Primary Adrenal Insufficiency in Acute Progressive Systemic Inflammation Accompanied by Latent Tuberculosis: A Case Report
Kasumi Nishikawa, Mizuki Nitta, Shoma Tanaka, Chiaki Sano, Ryuichi Ohta Cureus.2023;[Epub] CrossRef - What factors have impact on glucocorticoid replacement in adrenal insufficiency: a real-life study
S. Puglisi, A. Rossini, I. Tabaro, S. Cannavò, F. Ferrau’, M. Ragonese, G. Borretta, M. Pellegrino, F. Dughera, A. Parisi, A. Latina, A. Pia, M. Terzolo, G. Reimondo Journal of Endocrinological Investigation.2021; 44(4): 865. CrossRef - Adrenal insufficiency
Eystein S Husebye, Simon H Pearce, Nils P Krone, Olle Kämpe The Lancet.2021; 397(10274): 613. CrossRef - Towards the tailoring of glucocorticoid replacement in adrenal insufficiency: the Italian Society of Endocrinology Expert Opinion
A. M. Isidori, G. Arnaldi, M. Boscaro, A. Falorni, C. Giordano, R. Giordano, R. Pivonello, C. Pozza, E. Sbardella, C. Simeoli, C. Scaroni, A. Lenzi Journal of Endocrinological Investigation.2020; 43(5): 683. CrossRef - Novel ABCD1 Gene Mutation in a Korean Patient with X-Linked Adrenoleukodystrophy Presenting with Addison's Disease
Yun Kyung Cho, Seo-Young Lee, Sang-Wook Kim Endocrinology and Metabolism.2020; 35(1): 188. CrossRef - Encountering COVID-19 as Endocrinologists
Eun-Jung Rhee, Jung Hee Kim, Sun Joon Moon, Won-Young Lee Endocrinology and Metabolism.2020; 35(2): 197. CrossRef - Prednisolone is associated with a worse bone mineral density in primary adrenal insufficiency
Kathrin R Frey, Tina Kienitz, Julia Schulz, Manfred Ventz, Kathrin Zopf, Marcus Quinkler Endocrine Connections.2018; 7(6): 811. CrossRef - The potential role for infections in the pathogenesis of autoimmune Addison’s disease
A Hellesen, E Bratland Clinical and Experimental Immunology.2018; 195(1): 52. CrossRef - Evaluation and Treatment of Adrenal Dysfunction in the Primary Care Environment
Shannon Cole Nursing Clinics of North America.2018; 53(3): 385. CrossRef
- Clinical Study
- Characteristics of Korean Patients with Primary Adrenal Insufficiency: A Registry-Based Nationwide Survey in Korea
-
A Ram Hong, Ohk-Hyun Ryu, Seong Yeon Kim, Sang Wan Kim
-
Endocrinol Metab. 2017;32(4):466-474. Published online December 14, 2017
-
DOI: https://doi.org/10.3803/EnM.2017.32.4.466
-
-
6,502
View
-
65
Download
-
14
Web of Science
-
12
Crossref
-
Abstract
PDFSupplementary MaterialPubReader
- Background
Primary adrenal insufficiency (PAI) is a rare, potentially life-threatening condition. There are few Korean studies on PAI, and most have had small sample sizes. We aimed to examine the etiology, clinical characteristics, treatment, and mortality of PAI in Korean patients. MethodsA nationwide, multicenter, registry-based survey was conducted to identify adults diagnosed with or treated for PAI at 30 secondary or tertiary care institutions in Korea between 2000 and 2014. ResultsA total of 269 patients with PAI were identified. The prevalence of PAI was 4.17 per million. The estimated incidence was 0.45 per million per year. The mean age at diagnosis was 49.0 years, and PAI was more prevalent in men. Adrenal tuberculosis was the most common cause of PAI in patients diagnosed before 2000; for those diagnosed thereafter, adrenal metastasis and tuberculosis were comparable leading causes. The etiology of PAI was not identified in 34.9% of cases. Of the patients receiving glucocorticoid replacement therapy, prednisolone was more frequently administered than hydrocortisone (69.4% vs. 26.5%, respectively), and only 27.1% of all patients received fludrocortisone. We observed an increased prevalence of metabolic disease and osteoporosis during the follow-up period (median, 60.2 months). The observed overall mortality and disease-specific mortality rates were 11.9% and 3.1%, respectively. ConclusionThe prevalence of PAI is significantly lower in Koreans than in reports from Western countries. The high frequency undetermined etiology in patients with PAI suggests the need to reveal accurate etiology of PAI in Korea.
-
Citations
Citations to this article as recorded by
- Genetic and phenotypic spectrum of non-21-hydroxylase-deficiency primary adrenal insufficiency in childhood: data from 111 Chinese patients
Ying Duan, Wanqi Zheng, Yu Xia, Huiwen Zhang, Lili Liang, Ruifang Wang, Yi Yang, Kaichuang Zhang, Deyun Lu, Yuning Sun, Lianshu Han, Yongguo Yu, Xuefan Gu, Yu Sun, Bing Xiao, Wenjuan Qiu Journal of Medical Genetics.2024; 61(1): 27. CrossRef - Approach to the Patient: Diagnosis of Primary Adrenal Insufficiency in Adults
Marianne Øksnes, Eystein S Husebye The Journal of Clinical Endocrinology & Metabolism.2023; 109(1): 269. CrossRef - Epidemiology and Causes of Primary Adrenal Insufficiency in Children: A Population-Based Study
Joonatan Borchers, Eero Pukkala, Outi Mäkitie, Saila Laakso The Journal of Clinical Endocrinology & Metabolism.2023; 108(11): 2879. CrossRef - Primary Adrenal Insufficiency in Acute Progressive Systemic Inflammation Accompanied by Latent Tuberculosis: A Case Report
Kasumi Nishikawa, Mizuki Nitta, Shoma Tanaka, Chiaki Sano, Ryuichi Ohta Cureus.2023;[Epub] CrossRef - What factors have impact on glucocorticoid replacement in adrenal insufficiency: a real-life study
S. Puglisi, A. Rossini, I. Tabaro, S. Cannavò, F. Ferrau’, M. Ragonese, G. Borretta, M. Pellegrino, F. Dughera, A. Parisi, A. Latina, A. Pia, M. Terzolo, G. Reimondo Journal of Endocrinological Investigation.2021; 44(4): 865. CrossRef - Adrenal insufficiency
Eystein S Husebye, Simon H Pearce, Nils P Krone, Olle Kämpe The Lancet.2021; 397(10274): 613. CrossRef - Towards the tailoring of glucocorticoid replacement in adrenal insufficiency: the Italian Society of Endocrinology Expert Opinion
A. M. Isidori, G. Arnaldi, M. Boscaro, A. Falorni, C. Giordano, R. Giordano, R. Pivonello, C. Pozza, E. Sbardella, C. Simeoli, C. Scaroni, A. Lenzi Journal of Endocrinological Investigation.2020; 43(5): 683. CrossRef - Novel ABCD1 Gene Mutation in a Korean Patient with X-Linked Adrenoleukodystrophy Presenting with Addison's Disease
Yun Kyung Cho, Seo-Young Lee, Sang-Wook Kim Endocrinology and Metabolism.2020; 35(1): 188. CrossRef - Encountering COVID-19 as Endocrinologists
Eun-Jung Rhee, Jung Hee Kim, Sun Joon Moon, Won-Young Lee Endocrinology and Metabolism.2020; 35(2): 197. CrossRef - Prednisolone is associated with a worse bone mineral density in primary adrenal insufficiency
Kathrin R Frey, Tina Kienitz, Julia Schulz, Manfred Ventz, Kathrin Zopf, Marcus Quinkler Endocrine Connections.2018; 7(6): 811. CrossRef - The potential role for infections in the pathogenesis of autoimmune Addison’s disease
A Hellesen, E Bratland Clinical and Experimental Immunology.2018; 195(1): 52. CrossRef - Evaluation and Treatment of Adrenal Dysfunction in the Primary Care Environment
Shannon Cole Nursing Clinics of North America.2018; 53(3): 385. CrossRef
- Clinical Guidelines for the Management of Adrenal Incidentaloma
-
Jung-Min Lee, Mee Kyoung Kim, Seung-Hyun Ko, Jung-Min Koh, Bo-Yeon Kim, Sang Wan Kim, Soo-Kyung Kim, Hae Jin Kim, Ohk-Hyun Ryu, Juri Park, Jung Soo Lim, Seong Yeon Kim, Young Kee Shong, Soon Jib Yoo
-
Endocrinol Metab. 2017;32(2):200-218. Published online June 23, 2017
-
DOI: https://doi.org/10.3803/EnM.2017.32.2.200
-
-
18,359
View
-
755
Download
-
83
Web of Science
-
82
Crossref
-
Abstract
PDFPubReader
An adrenal incidentaloma is an adrenal mass found in an imaging study performed for other reasons unrelated to adrenal disease and often accompanied by obesity, diabetes, or hypertension. The prevalence and incidence of adrenal incidentaloma increase with age and are also expected to rise due to the rapid development of imaging technology and frequent imaging studies. The Korean Endocrine Society is promoting an appropriate practice guideline to meet the rising incidence of adrenal incidentaloma, in cooperation with the Korean Adrenal Gland and Endocrine Hypertension Study Group. In this paper, we discuss important core issues in managing the patients with adrenal incidentaloma. After evaluating core proposition, we propose the most critical 20 recommendations from the initially organized 47 recommendations by Delphi technique.
-
Citations
Citations to this article as recorded by
- The improvement of postoperative blood pressure and associated factors in patients with hormone‐negative adrenal adenoma and hypertension
Jiaxing Sun, Yingchun Dong, Hanbo Wang, Xudong Guo, Ning Suo, Shangjian Li, Xiangbin Ren, Shaobo Jiang Journal of Surgical Oncology.2024; 129(6): 1073. CrossRef - Clinical features and treatment options for pediatric adrenal incidentalomas: a retrospective single center study
Xiaojiang Zhu, Saisai Liu, Yimin Yuan, Nannan Gu, Jintong Sha, Yunfei Guo, Yongji Deng BMC Pediatrics.2024;[Epub] CrossRef - Mineral metabolism assays and osteoporotic fracture risk
evaluation in menopausal population diagnosed with adrenal
incidentalomas: a sub-analysis of PRECES study
Alexandra-Ioana Trandafir, Mihaela Stanciu, Ana Valea, Oana-Claudia Sima, Claudiu Nistor, Mădălina Gabriela Iliescu, Ileana Ciobanu, Florina Ligia Popa, Mara Carsote Balneo and PRM Research Journal.2024; 15(Vol.15, no): 692. CrossRef - Assessment of the diagnostic efficacy of radiological and functional evaluation of primary adrenal mass and its’ surgical outcomes
Yash Manharlal Tilala, Sabyasachi Panda, Abhilekh Tripathi, Sachin Sharma, Amiya Shankar Paul, Sanjay Choudhuri, Samir Swain Urologia Journal.2024;[Epub] CrossRef - Demographic and Clinical Characteristics of Patients with Adrenal Incidentaloma from a Single Center in South India: A Retrospective Study
Abhijeet B Jawanjal, Siddarth Sadananda, Nikitha Sriramaneni, Y. P. Ganavi, Pramila Kalra, Chitra Selvan, P. R. Manjunath, Praneethi K. Shetty Annals of African Medicine.2024; 23(4): 567. CrossRef - Characterizing incidental mass lesions in abdominal dual-energy CT compared to conventional contrast-enhanced CT
Jack Junchi Xu, Peter Sommer Ulriksen, Camilla Wium Bjerrum, Michael Patrick Achiam, Timothy Andrew Resch, Lars Lönn, Kristoffer Lindskov Hansen Acta Radiologica.2023; 64(3): 945. CrossRef - Metastatic Adrenal PEComa: Case Report and Short Review of the Literature
Enrico Battistella, Luca Pomba, Marica Mirabella, Michele Gregianin, Antonio Scapinello, Marco Volante, Antonio Toniato Medicina.2023; 59(1): 149. CrossRef - Surgical management and outcomes of spinal metastasis of malignant adrenal tumor: A retrospective study of six cases and literature review
Xiangzhi Ni, Jing Wang, Jiashi Cao, Kun Zhang, Shuming Hou, Xing Huang, Yuanjin Song, Xin Gao, Jianru Xiao, Tielong Liu Frontiers in Oncology.2023;[Epub] CrossRef - An adrenal incidentaloma that had appeared to produce dehydroepiandrosterone-sulfate in excess before immunohistochemical study of the tumor
Toshihide Yamamoto, Takuma Kimura, Yuki Kubo, Shin-ichi Nakatsuka, Hiromasa Harada, Takashi Suzuki, Hironobu Sasano Endocrine Journal.2023; 70(1): 43. CrossRef - Mortality Not Increased in Patients With Nonfunctional Adrenal Adenomas: A Matched Cohort Study
Albin Kjellbom, Ola Lindgren, Malin Danielsson, Henrik Olsen, Magnus Löndahl The Journal of Clinical Endocrinology & Metabolism.2023; 108(8): e536. CrossRef - Construction of a novel clinical nomogram to predict cancer-specific survival in patients with primary malignant adrenal tumors: a large population-based retrospective study
Mingzhen Li, Xiaoying Duan, Di You, Linlin Liu Frontiers in Medicine.2023;[Epub] CrossRef - Primary Aldosteronism Prevalence – An Unfolding
Story
Suranut Charoensri, Adina F. Turcu Experimental and Clinical Endocrinology & Diabetes.2023; 131(07/08): 394. CrossRef - Management of Adrenal Cortical Adenomas: Assessment of Bone Status in Patients with (Non-Functioning) Adrenal Incidentalomas
Alexandra-Ioana Trandafir, Mihaela Stanciu, Simona Elena Albu, Vasile Razvan Stoian, Irina Ciofu, Cristian Persu, Claudiu Nistor, Mara Carsote Journal of Clinical Medicine.2023; 12(13): 4244. CrossRef - Clinical manifestations of functionally autonomous cortisol secretion in patients with adrenal masse
T. R. Chzhen, T. P. Kiseleva Ural Medical Journal.2023; 22(3): 13. CrossRef - Tumor enlargement in adrenal incidentaloma is related to glaucoma: a new prognostic feature?
M. Caputo, T. Daffara, A. Ferrero, M. Romanisio, E. Monti, C. Mele, M. Zavattaro, S. Tricca, A. Siani, A. Clemente, C. Palumbo, S. De Cillà, A. Carriero, A. Volpe, P. Marzullo, G. Aimaretti, F. Prodam Journal of Endocrinological Investigation.2023; 47(2): 377. CrossRef - Adrenal ganglioneuroma: Features and outcomes of cases series
Pei Li, Rongchang Zhang, Guang Wang, Jiongming Li Asian Journal of Surgery.2023; 46(11): 5272. CrossRef - Recent Updates on the Management of Adrenal Incidentalomas
Seung Shin Park, Jung Hee Kim Endocrinology and Metabolism.2023; 38(4): 373. CrossRef - Adrenal malakoplakia a rare lesion that mimics a neoplasm
Orión Erenhú Rodríguez González, Jesus Eduardo Osorio, Edgar Iván Bravo Castro Urology Case Reports.2023; 51: 102568. CrossRef - LC-MS based simultaneous profiling of adrenal hormones of steroids, catecholamines, and metanephrines
Jongsung Noh, Chaelin Lee, Jung Hee Kim, Seung Woon Myung, Man Ho Choi Journal of Lipid Research.2023; 64(11): 100453. CrossRef - Incidentaloma adrenal. Del hallazgo casual al diagnóstico definitivo
Mercedes Retamal Ortíz, Ana Belén Vicario Parada, Elena Vázquez Jarén Actualización en Medicina de Familia.2023;[Epub] CrossRef - Diagnosis and management of adrenal incidentaloma: use of clinical judgment and evidence in dialog with the patient
Yusaku Yoshida, Kiyomi Horiuchi, Michio Otsuki, Takahiro Okamoto Surgery Today.2023;[Epub] CrossRef - Can MDCT Enhancement Patterns Be Helpful in Differentiating Secretory from Non-Functional Adrenal Adenoma?
Svetlana Kocic, Vladimir Vukomanovic, Aleksandar Djukic, Jovica Saponjski, Dusan Saponjski, Vuk Aleksic, Vesna Ignjatovic, Katarina Vuleta Nedic, Vladan Markovic, Radisa Vojinovic Medicina.2023; 60(1): 72. CrossRef - Computer-assisted Reporting and Decision Support Increases Compliance with Follow-up Imaging and Hormonal Screening of Adrenal Incidentalomas
Renata R. Almeida, Bernardo C. Bizzo, Ramandeep Singh, Katherine P. Andriole, Tarik K. Alkasab Academic Radiology.2022; 29(2): 236. CrossRef - Incidental Adrenal Masses: Adherence to Guidelines and Methods to Improve Initial Follow-Up: A Systematic Review
Timothy Feeney, Andrea Madiedo, Philip E. Knapp, Avneesh Gupta, David McAneny, Frederick Thurston Drake Journal of Surgical Research.2022; 269: 18. CrossRef - Incidental Adrenal Lesions May Not Always Require Further Imaging Work-up
Deborah A. Baumgarten Radiology.2022; 302(1): 138. CrossRef - Adrenal Nodules Detected at Staging CT in Patients with Resectable Gastric Cancers Have a Low Incidence of Malignancy
Hae Young Kim, Won Chang, Yoon Jin Lee, Ji Hoon Park, Jungheum Cho, Hee Young Na, Hyungwoo Ahn, Sung Il Hwang, Hak Jong Lee, Young Hoon Kim, Kyoung Ho Lee Radiology.2022; 302(1): 129. CrossRef - Management of incidental adrenal nodules: a survey of abdominal radiologists conducted by the Society of Abdominal Radiology Disease-Focused Panel on Adrenal Neoplasms
Michael T. Corwin, Nicola Schieda, Erick M. Remer, Elaine M. Caoili Abdominal Radiology.2022; 47(4): 1360. CrossRef - Primary hyperaldosteronism: indications for screening
Novella M. Chikhladze Terapevticheskii arkhiv.2022; 94(1): 107. CrossRef - Pathophysiological Link between Insulin Resistance and Adrenal Incidentalomas
Jordan A. Higgs, Alyssa P. Quinn, Kevin D. Seely, Zeke Richards, Shad P. Mortensen, Cody S. Crandall, Amanda E. Brooks International Journal of Molecular Sciences.2022; 23(8): 4340. CrossRef - Can Radiomics Provide Additional Diagnostic Value for Identifying Adrenal Lipid-Poor Adenomas From Non-Adenomas on Unenhanced CT?
Binhao Zhang, Huangqi Zhang, Xin Li, Shengze Jin, Jiawen Yang, Wenting Pan, Xue Dong, Jin Chen, Wenbin Ji Frontiers in Oncology.2022;[Epub] CrossRef - Adrenal Surgery in the Era of Multidisciplinary Endocrine Tumor
Boards
Costanza Chiapponi, Daniel Pinto Dos Santos, Milan Janis Michael Hartmann, Matthias Schmidt, Michael Faust, Roger Wahba, Christiane Josephine Bruns, Anne Maria Schultheis, Hakan Alakus Hormone and Metabolic Research.2022; 54(05): 294. CrossRef - Optimal and novel imaging of the adrenal glands
Patrick J. Navin, Michael R. Moynagh Current Opinion in Endocrinology, Diabetes & Obesity.2022; 29(3): 253. CrossRef - Adrenal Tumors in Young Adults: Case Reports and Literature Review
Małgorzata Zdrojewska, Emilia Mech-Siebieszuk, Renata Świątkowska-Stodulska, Bartosz Regent, Michał Kunc, Łukasz Zdrojewski, Krzysztof Sworczak Medicina.2022; 58(6): 746. CrossRef - Incidence of malignancy in adrenal nodules detected on staging CTs of patients with potentially resectable colorectal cancer
Hae Young Kim, Yoon Jin Lee, Won Chang, Ji Hoon Park, Jungheum Cho, Hyeon Jeong Oh, Young Hoon Kim, Kyoung Ho Lee European Radiology.2022; 32(12): 8560. CrossRef - Appendiceal Incidentalomas: Prevalence, Radiographic Characteristics, Management, and Outcomes
Adam Kelly, Stacy O’Connor, Diana Kane, Chiang-Ching Huang, Harveshp Mogal Annals of Surgical Oncology.2022; 29(13): 8265. CrossRef - Laparoscopic large adrenal mass resection: why we should be more careful?
Mohsen Varyani, Mahmood Parvin, Hamidreza Akbari Gilani African Journal of Urology.2022;[Epub] CrossRef - Serum Visfatin/NAMPT as a Potential Risk Predictor for Malignancy of Adrenal Tumors
Nadia Sawicka-Gutaj, Hanna Komarowska, Dawid Gruszczyński, Aleksandra Derwich, Anna Klimont, Marek Ruchała Journal of Clinical Medicine.2022; 11(19): 5563. CrossRef - Application of radiomics in adrenal incidentaloma: a literature review
Cheng Li, Yan Fu, Xiaoping Yi, Xiao Guan, Longfei Liu, Bihong T. Chen Discover Oncology.2022;[Epub] CrossRef - Hormone-inactive adrenal tumors in clinician’s practice
T. R. Chzhen, T. P. Kiseleva Perm Medical Journal.2022; 39(5): 48. CrossRef - The diagnostic value of salivary cortisol and salivary cortisone in patients with suspected hypercortisolism
Vendela Berndt, Per Dahlqvist, Jennie de Verdier, Henrik Ryberg, Oskar Ragnarsson Frontiers in Endocrinology.2022;[Epub] CrossRef - The Role of Intraoperative Indocyanine Green (ICG) and Preoperative 3-Dimensional (3D) Reconstruction in Laparoscopic Adrenalectomy: A Propensity Score-matched Analysis
Giuseppe Palomba, Vincenza Paola Dinuzzi, Francesca Pegoraro, Roberto Ivan Troisi, Roberto Montalti, Giovanni Domenico De Palma, Giovanni Aprea Surgical Laparoscopy, Endoscopy & Percutaneous Techniques.2022; 32(6): 643. CrossRef - The Etiological Profile of Adrenal Incidentalomas
Fatima-Zahra Lahmamssi, Loubna Saadaoui, Hayat Aynaou, Houda Salhi, Hanan El Ouahabi Cureus.2022;[Epub] CrossRef - Forty Years Together, New Leap Forward! The 40th Anniversary of the Korean Endocrine Society
Jong Chul Won, Ki-Hyun Baek Endocrinology and Metabolism.2022; 37(6): 851. CrossRef - Conduite à tenir face à un fortuitome surrénalien chez le chien ou le chat
Diane Pichard, Ghita Benckekroun Le Nouveau Praticien Vétérinaire canine & féline.2022; 19(82): 40. CrossRef - Laparoscopic transperitoneal adrenalectomy: a comparative study of different techniques for vessel sealing
Luca Cardinali, Edlira Skrami, Elisa Catani, Flavia Carle, Monica Ortenzi, Andrea Balla, Mario Guerrieri Surgical Endoscopy.2021; 35(2): 673. CrossRef - Epidemiology and Comorbidity of Adrenal Cushing Syndrome: A Nationwide Cohort Study
Chang Ho Ahn, Jung Hee Kim, Man Young Park, Sang Wan Kim The Journal of Clinical Endocrinology & Metabolism.2021; 106(3): e1362. CrossRef - Urine steroid profile as a new promising tool for the evaluation of adrenal tumors. Literature review
Marta Araujo-Castro, Pablo Valderrábano, Héctor F. Escobar-Morreale, Felicia A. Hanzu, Gregori Casals Endocrine.2021; 72(1): 40. CrossRef - A Rare Neoplasm: Primary Adrenal Leiomyosarcoma
Jack T. Barnett, Christine W. Liaw, Reza Mehrazin Urology.2021; 148: e11. CrossRef - Adrenal Ganglioneuroma Presenting as an Incidentaloma in an Adolescent Patient
Sonia G. Sharma, Steven N. Levine, Xin Gu AACE Clinical Case Reports.2021; 7(1): 61. CrossRef - Feasibility of Iodine-131 6β-Methyl-Iodo-19 Norcholesterol (NP-59) Scintigraphy to Complement Adrenal Venous Sampling in Management of Primary Aldosteronism: A Case Series
Jeongmin Lee, Jeonghoon Ha, Sang-Kuon Lee, Hye Lim Park, Sung-Hoon Kim, Dong-Jun Lim, Jung Min Lee, Sang-Ah Chang, Moo Il Kang, Min-Hee Kim International Journal of General Medicine.2021; Volume 14: 673. CrossRef - Best Achievements in Pituitary and Adrenal Diseases in 2020
Chang Ho Ahn, Jung Hee Kim Endocrinology and Metabolism.2021; 36(1): 51. CrossRef - Adrenal surgery: Review of 35 years experience in a single centre
Enrico Battistella, Stefania Ferrari, Luca Pomba, Antonio Toniato Surgical Oncology.2021; 37: 101554. CrossRef - Adrenocortical Carcinoma: A Case of Missed Diagnosis
Yusef Hazimeh, Carlie Sigel, Carsello Carie, Mathew Leinung, Zaynab Khalaf Cureus.2021;[Epub] CrossRef - Imagerie fonctionnelle en endocrinologie : nouveaux paradigmes à l’horizon 2020
E. Marchal Médecine Nucléaire.2021; 45(3): 158. CrossRef - Adrenal Incidentaloma
Caren G. Solomon, Electron Kebebew New England Journal of Medicine.2021; 384(16): 1542. CrossRef - Can Hematological Parameters Play a Role in the Differential Diagnosis of Adrenal Tumors?
Mehmet Gürkan Arıkan, Göktan Altuğ Öz, Nur Gülce İşkan, Necdet Süt, İlkan Yüksel, Ersan Arda Uro.2021; 1(2): 39. CrossRef - Incidental Adrenal Nodules
Daniel I. Glazer, Michael T. Corwin, William W. Mayo-Smith Radiologic Clinics of North America.2021; 59(4): 591. CrossRef - Antioxidant Barrier and Oxidative Damage to Proteins, Lipids, and DNA/RNA in Adrenal Tumor Patients
Barbara Choromańska, Piotr Myśliwiec, Tomasz Kozłowski, Magdalena Łuba, Piotr Wojskowicz, Jacek Dadan, Hanna Myśliwiec, Katarzyna Choromańska, Anna Gibała, Anna Starzyńska, Małgorzata Żendzian-Piotrowska, Anna Zalewska, Mateusz Maciejczyk, Jos L. Quiles Oxidative Medicine and Cellular Longevity.2021;[Epub] CrossRef - Laparoscopic Retroperitoneoscopic Removal of an Adrenal Hemangioma: a Case Report
Kristin McCoy, Katherine Howe, Daniel Tershak Journal of Endocrine Surgery.2021; 21(3): 70. CrossRef - Metabolic Subtyping of Adrenal Tumors: Prospective Multi-Center Cohort Study in Korea
Eu Jeong Ku, Chaelin Lee, Jaeyoon Shim, Sihoon Lee, Kyoung-Ah Kim, Sang Wan Kim, Yumie Rhee, Hyo-Jeong Kim, Jung Soo Lim, Choon Hee Chung, Sung Wan Chun, Soon-Jib Yoo, Ohk-Hyun Ryu, Ho Chan Cho, A Ram Hong, Chang Ho Ahn, Jung Hee Kim, Man Ho Choi Endocrinology and Metabolism.2021; 36(5): 1131. CrossRef - Cross-Talk Between Nitrosative Stress, Inflammation and Hypoxia-Inducible Factor in Patients with Adrenal Masses
Barbara Choromańska, Piotr Myśliwiec, Tomasz Kozłowski, Magdalena Łuba, Piotr Wojskowicz, Jacek Dadan, Hanna Myśliwiec, Katarzyna Choromańska, Katarzyna Makarewicz, Anna Zalewska, Mateusz Maciejczyk Journal of Inflammation Research.2021; Volume 14: 6317. CrossRef - Cirugía laparoscópica en incidentaloma suprarrenal para el cirujano general: serie de casos
Martín Adrián Bolívar-Rodríguez, Marcel Antonio Cázarez-Aguilar, Pedro Alejandro Magaña-Zavala, Francisco Magaña-Olivas, José Martín Niebla-Moreno Revista Mexicana de Cirugía Endoscópica.2021; 22(1): 8. CrossRef - Adrenal adenomas: what to do with them? Review 2
S. Rybakov INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine).2021; 17(3): 241. CrossRef - Laparoscopic adrenalectomy for giant adrenal tumours
Alessio Giordano, Giovanni Alemanno, Carlo Bergamini, Andrea Valeri, Paolo Prosperi Journal of Minimal Access Surgery.2021; 17(1): 76. CrossRef - Is Follow-up of Adrenal Incidentalomas Always Mandatory?
Giuseppe Reimondo, Alessandra Muller, Elisa Ingargiola, Soraya Puglisi, Massimo Terzolo Endocrinology and Metabolism.2020; 35(1): 26. CrossRef - Imaging Findings of Primary Adrenal Leiomyosarcoma: A Case Report
Hye Ran Yoon, Dong Hee Park Journal of the Korean Society of Radiology.2020; 81(2): 459. CrossRef - WFUMB position paper on the management incidental findings: adrenal incidentaloma
Christoph F. Dietrich, Jean Michel Correas, Yi Dong, Christian Nolsoe, Susan Campbell Westerway, Christian Jenssen Ultrasonography.2020; 39(1): 11. CrossRef - A nationwide survey of adrenal incidentalomas in Japan: the first report of clinical and epidemiological features
Takamasa Ichijo, Hajime Ueshiba, Hajime Nawata, Toshihiko Yanase Endocrine Journal.2020; 67(2): 141. CrossRef - Mimics, pitfalls, and misdiagnoses of adrenal masses on CT and MRI
Khaled M. Elsayes, Mohab M. Elmohr, Sanaz Javadi, Christine O. Menias, Erick M. Remer, Ajaykumar C. Morani, Akram M. Shaaban Abdominal Radiology.2020; 45(4): 982. CrossRef - Adrenal Incidentaloma
Mark Sherlock, Andrew Scarsbrook, Afroze Abbas, Sheila Fraser, Padiporn Limumpornpetch, Rosemary Dineen, Paul M Stewart Endocrine Reviews.2020; 41(6): 775. CrossRef - A Web Application for Adrenal Incidentaloma Identification, Tracking, and Management Using Machine Learning
Wasif Bala, Jackson Steinkamp, Timothy Feeney, Avneesh Gupta, Abhinav Sharma, Jake Kantrowitz, Nicholas Cordella, James Moses, Frederick Thurston Drake Applied Clinical Informatics.2020; 11(04): 606. CrossRef - Presentation and outcome of patients with an adrenal mass: A retrospective observational study
Nadeema Rafiq, Tauseef Nabi, SajadAhmad Dar, Shahnawaz Rasool Clinical Cancer Investigation Journal.2020; 9(5): 198. CrossRef - Evaluation of Functionality and Growth Rates in Adrenal Incidentalomas: Single Center Experience
Suna AVCI, Yüksel Aslı OZTURKMEN, Sayid ZUHUR, Gulkan OZKAN, Elif GUVEN, Nazan DEMİR, Yuksel ALTUNTAS Phoenix Medical Journal.2020; 2(3): 125. CrossRef - Percutaneous Adrenal Radiofrequency Ablation: A Short Review for Endocrinologists
Byung Kwan Park Endocrinology and Metabolism.2020; 35(4): 750. CrossRef - Autonomous cortisol secretion in adrenal incidentalomas
Marta Araujo-Castro, Miguel Antonio Sampedro Núñez, Mónica Marazuela Endocrine.2019; 64(1): 1. CrossRef - Primary adrenal schwannoma: a series of 31 cases emphasizing their clinicopathologic features and favorable prognosis
Jun Zhou, Dandan Zhang, Wencai Li, Luting Zhou, Haimin Xu, Saifang Zheng, Chaofu Wang Endocrine.2019; 65(3): 662. CrossRef - Challenging risk factors for right and left laparoscopic adrenalectomy: A single centre experience with 272 cases
Kadir Omur Gunseren, Mehmet Cagatay Cicek, Hakan Vuruskan, Yakup Kordan, Ismet Yavascaoglu International braz j urol.2019; 45(4): 747. CrossRef - A case report on 111In chloride bone marrow scintigraphy in management of adrenal myelolipoma
Tatsuya Yamamoto, Mitsuru Koizumi, Atsushi Kohno, Noboru Numao, Kentaro Inamura Medicine.2019; 98(8): e14625. CrossRef - PRACTICAL ASPECTS OF LAPAROSCOPIC ADRENALECTOMY IN CHILDREN WITH BENIGN ADRENAL TUMORS
I. V. Poddubny, R. S. Oganesyan, K. N. Tolstov, M. A. Kareva Russian Journal of Pediatric Surgery.2019; 23(5): 248. CrossRef - Incidental neuroblastoma with bilateral retinoblastoma: what are the chances?
Kelsey Roelofs, Furqan Shaikh, William Astle, Brenda L. Gallie, Sameh E. Soliman Ophthalmic Genetics.2018; 39(3): 410. CrossRef - Surgical Considerations in Subclinical Cushing’s Syndrome. When is it Time to Operate?
Alexander M. Nixon, C Aggeli, C Tserkezis, GN Zografos Hellenic Journal of Surgery.2018; 90(1): 27. CrossRef - Adrenal incidentaloma – diagnostic and treating problem – own experience
Ryszard Pogorzelski, Krzysztof Celejewski, Sadegh Toutounchi, Ewa Krajewska, Tomasz Wołoszko, Małgorzata Szostek, Wawrzyniec Jakuczun, Patryk Fiszer, Małgorzata Legocka, Zbigniew Gałązka Open Medicine.2018; 13(1): 281. CrossRef
- Clinical Study
- Effect of Pitavastatin Treatment on ApoB-48 and Lp-PLA2 in Patients with Metabolic Syndrome: Substudy of PROspective Comparative Clinical Study Evaluating the Efficacy and Safety of PITavastatin in Patients with Metabolic Syndrome
-
Hyo-Sun Lee, Chang Hee Jung, Sung Rae Kim, Hak Chul Jang, Cheol-Young Park
-
Endocrinol Metab. 2016;31(1):120-126. Published online March 16, 2016
-
DOI: https://doi.org/10.3803/EnM.2016.31.1.120
-
-
4,095
View
-
36
Download
-
6
Web of Science
-
6
Crossref
-
Abstract
PDFPubReader
- Background
Apolipoprotein (Apo) B-48 is an intestinally derived lipoprotein that is expected to be a marker for cardiovascular disease (CVD). Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a vascular-specific inflammatory marker and important risk predictor of CVD. The aim of this study was to explore the effect of pitavastatin treatment and life style modification (LSM) on ApoB-48 and Lp-PLA2 levels in metabolic syndrome (MS) patients at relatively low risk for CVD, as a sub-analysis of a previous multi-center prospective study. MethodsWe enrolled 75 patients with MS from the PROPIT study and randomized them into two treatment groups: 2 mg pitavastatin daily+intensive LSM or intensive LSM only. We measured the change of lipid profiles, ApoB-48 and Lp-PLA2 for 48 weeks. ResultsTotal cholesterol, low density lipoprotein cholesterol, non-high density lipoprotein cholesterol, and ApoB-100/A1 ratio were significantly improved in the pitavastatin+LSM group compared to the LSM only group (P≤0.001). Pitavastatin+LSM did not change the level of ApoB-48 in subjects overall, but the level of ApoB-48 was significantly lower in the higher mean baseline value group of ApoB-48. The change in Lp-PLA2 was not significant after intervention in either group after treatment with pitavastatin for 1 year. ConclusionPitavastatin treatment and LSM significantly improved lipid profiles, ApoB-100/A1 ratio, and reduced ApoB-48 levels in the higher mean baseline value group of ApoB-48, but did not significantly alter the Lp-PLA2 levels.
-
Citations
Citations to this article as recorded by
- A comprehensive review on the lipid and pleiotropic effects of pitavastatin
Amirhossein Sahebkar, Nasim Kiaie, Armita Mahdavi Gorabi, Massimo R. Mannarino, Vanessa Bianconi, Tannaz Jamialahmadi, Matteo Pirro, Maciej Banach Progress in Lipid Research.2021; 84: 101127. CrossRef - Change in ALT levels after administration of HMG‐CoA reductase inhibitors to subjects with pretreatment levels three times the upper normal limit in clinical practice
Hyunah Kim, Hyeseon Lee, Tong Min Kim, So Jung Yang, Seo Yeon Baik, Seung‐Hwan Lee, Jae‐Hyoung Cho, Hyunyong Lee, Hyeon Woo Yim, In Young Choi, Kun‐Ho Yoon, Hun‐Sung Kim Cardiovascular Therapeutics.2018;[Epub] CrossRef - Articles inEndocrinology and Metabolismin 2016
Won-Young Lee Endocrinology and Metabolism.2017; 32(1): 62. CrossRef - Use of Moderate‐Intensity Statins for Low‐Density Lipoprotein Cholesterol Level above 190 mg/dL at Baseline in Koreans
Hun‐Sung Kim, Hyeseon Lee, Sue Hyun Lee, Yoo Jin Jeong, Tong Min Kim, So Jung Yang, Sun Jung Baik, Hyunah Kim, Seung‐Hwan Lee, Jae Hyoung Cho, In‐Young Choi, Kun‐Ho Yoon, Ju Han Kim Basic & Clinical Pharmacology & Toxicology.2017; 121(4): 272. CrossRef - Another statin option in HIV
Philip E Tarr, Helen Kovari The Lancet HIV.2017; 4(7): e278. CrossRef - Clinical Benefits of Pitavastatin: Focus On Patients With Diabetes Or at Risk of Developing Diabetes
Vivencio Barrios, Carlos Escobar Future Cardiology.2016; 12(4): 449. CrossRef
- Obesity and Metabolism
- 2014 Clinical Practice Guidelines for Overweight and Obesity in Korea
-
Mee Kyoung Kim, Won-Young Lee, Jae-Heon Kang, Jee-Hyun Kang, Bom Taeck Kim, Seon Mee Kim, Eun Mi Kim, Sang-Hoon Suh, Hye Jung Shin, Kyu Rae Lee, Ki Young Lee, Sang Yeoup Lee, Seon Yeong Lee, Seong-Kyu Lee, Chang Beom Lee, Sochung Chung, In Kyung Jeong, Kyung Yul Hur, Sung Soo Kim, Jeong-taek Woo
-
Endocrinol Metab. 2014;29(4):405-409. Published online December 29, 2014
-
DOI: https://doi.org/10.3803/EnM.2014.29.4.405
-
-
10,199
View
-
93
Download
-
231
Web of Science
-
250
Crossref
-
Abstract
PDFPubReader
The dramatic increase in the prevalence of obesity and its accompanying comorbidities are major health concerns in Korea. Obesity is defined as a body mass index ≥25 kg/m2 in Korea. Current estimates are that 32.8% of adults are obese: 36.1% of men and 29.7% of women. The prevalence of being overweight and obese in national surveys is increasing steadily. Early detection and the proper management of obesity are urgently needed. Weight loss of 5% to 10% is the standard goal. In obese patients, control of cardiovascular risk factors deserves the same emphasis as weight-loss therapy. Since obesity is multifactorial, proper care of obesity requires a coordinated multidisciplinary treatment team, as a single intervention is unlikely to modify the incidence or natural history of obesity.
-
Citations
Citations to this article as recorded by
- Obesity and Metabolism
- 2014 Clinical Practice Guidelines for Overweight and Obesity in Korea
-
Mee Kyoung Kim, Won-Young Lee, Jae-Heon Kang, Jee-Hyun Kang, Bom Taeck Kim, Seon Mee Kim, Eun Mi Kim, Sang-Hoon Suh, Hye Jung Shin, Kyu Rae Lee, Ki Young Lee, Sang Yeoup Lee, Seon Yeong Lee, Seong-Kyu Lee, Chang Beom Lee, Sochung Chung, In Kyung Jeong, Kyung Yul Hur, Sung Soo Kim, Jeong-taek Woo
-
Endocrinol Metab. 2014;29(4):405-409. Published online December 29, 2014
-
DOI: https://doi.org/10.3803/EnM.2014.29.4.405
-
-
10,199
View
-
93
Download
-
231
Web of Science
-
250
Crossref
-
Abstract
PDFPubReader
The dramatic increase in the prevalence of obesity and its accompanying comorbidities are major health concerns in Korea. Obesity is defined as a body mass index ≥25 kg/m2 in Korea. Current estimates are that 32.8% of adults are obese: 36.1% of men and 29.7% of women. The prevalence of being overweight and obese in national surveys is increasing steadily. Early detection and the proper management of obesity are urgently needed. Weight loss of 5% to 10% is the standard goal. In obese patients, control of cardiovascular risk factors deserves the same emphasis as weight-loss therapy. Since obesity is multifactorial, proper care of obesity requires a coordinated multidisciplinary treatment team, as a single intervention is unlikely to modify the incidence or natural history of obesity.
-
Citations
Citations to this article as recorded by
|